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Abstract 
  
 
 The study of retroviruses and their lifecycle has contributed immensely to our 
knowledge of the world of biology and medicine.  The central dogma of the basic flow of 
genetic information was shattered when the discovery that retroviruses copy their RNA 
genome into DNA was made.  The same enzyme that performs this step, reverse 
transcriptase (RT), also revolutionized molecular biology when it was used as a tool to 
generate full length cDNA clones of expressed genes.  The impact of retroviruses on the 
medical field has been extremely exciting as the ideas of using retroviral vectors to 
deliver genes providing long term expression is becoming a reality in the field of gene 
therapy.   
 
 The following study delves further into many aspects of the retroviral lifecycle 
including entry, reverse transcription, and alternative splicing.  Recent evidence has 
shown that cathepsin B cleaves the Moloney Murine Leukemia Virus (MoMLV) surface 
unit (SU) and may be important for the membrane fusion step during viral entry.  Here I 
present evidence that other host cell cathepsins including L, S, and D are able cleave 
MoMLV SU at specific sites.  Many of the cathepsins tested appear to cleave in the very 
same region as cathepsin B, suggesting they may perform a similar function.   
 
The second phase of this study focuses on the reverse transcription step of the 
retroviral lifecycle.  Similar to other polymerases, retroviral RT requires a primer to 
initiate transcription.  Retroviruses use host cell tRNAs which must first be 
deaminoacylated before the RT enzyme can begin reverse transcription.  This work 
examines the crystal structure of human immunodeficiency virus type one (HIV-1) RT 
for a possible hydrolase site that is capable of deaminoacylating its primer tRNA.  The 
hydrolase activity of HIV-1 RT was investigated when a charged tRNA was annealed to a 
genomic template.  Furthermore recombinant HIV-1 virions were investigated for the 
presence of two cellular proteins histidine triad nucleotide-binding protein and human 
peptidyl-tRNA hydrolase 2 that may also play a role in deaminoacylation of the primer 
tRNA. 
 
This study culminates by examining the cis-elements that control alternative 
splicing in MoMLV.  The splice donor (SD) and splice acceptor (SA) sites within 
MoMLV poorly match the consensus sequence for optimal splicing.  Mutagenesis was 
performed using a MoMLV envelope expression plasmid to alter the nucleotide sequence 
of the SD and SA to match the consensus sequence.  This resulted in an increase in 
envelope expression and viral infectivity of recombinant MoMLV. 
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Chapter 1.  Introduction   
 
 
Viruses 
 
 A virus is one of the smallest and simplest infectious agents.  Viruses infect an 
extremely wide variety of organisms including plants, animals, and bacteria.  Viruses are 
incapable of reproducing on their own and are obligate intracellular parasites. They rely 
on the machinery of the host cell to synthesize the viral proteins and in some cases even 
replicate the viral genome.  They are extremely simplistic organisms and in their most 
basic form consist of a small RNA or DNA genome, which is encased by a protein shell 
or capsid.  In addition to the capsid some viruses have an envelope that covers the outside 
of the virus.  The envelope is a lipid membrane that is acquired from the host cell 
membrane.  The simplest viruses encode for only four proteins while others encode a few 
hundred proteins [1]. 
 
 Viruses can only infect cells to which they can bind.  Attachment to a host cell 
requires a specific interaction between the viral surface proteins and a cellular receptor.  
The specificity of this interaction largely determines which cell types, tissues, and 
organisms a virus is capable of infecting.  After binding, the virus must cross the plasma 
membrane.  Enveloped and non-enveloped viruses utilize different mechanisms to 
accomplish this.  Enveloped viruses undergo a fusion event between the cellular 
membrane and the viral membrane.  This can occur at the plasma membrane or the virus 
can become internalized and fuse with the membrane of an internal organelle. The 
mechanisms used by non-enveloped viruses are not as well understood.  Non-enveloped 
viruses can directly puncture or generate a pore in the cell membrane [2], this can also 
occur at the plasma membrane or after internalization of the virus.  Once in the 
cytoplasm, a variety of pathways and mechanism are involved in the uncoating, 
replication, and assembly of progeny virus.   
 
 
Retroviruses 
 
 The family Retroviridae is a large group of enveloped, positive strand RNA 
viruses.  Retroviruses infect a wide range of animal and higher eukaryotic species causing 
a variety of diseases including tumors, leukemia, autoimmune disease, 
immunodeficiency, and neurological disorders.  A typical retrovirus particle           
(Figure 1-1A) ranges from 80-120 nm  in diameter. These particles are spherical in shape 
and consist of 1-2% RNA, about 35% lipids, and 65% protein [3]. The definitive 
characteristic of this family is the reverse transcription step during its life cycle. The 
replication of their genome is very different from other viruses; the flow of genetic 
information goes from RNA to DNA.  Retroviruses reverse transcribe their RNA genome 
into double stranded DNA, which is then integrated into the genome of the host cell. 
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A. 
 
 
 
B. 
 
 
 
 
 
Figure 1-1.  MLV particle and genome.  A)  A schematic diagram of MLV particle.  
TM, transmembrane components; SU, surface components; IN, integrase; CA, capsid 
protein; MA, matrix protein; NC, nucleocapsid protein; RT, reverse transcriptase.  B)  
Schematic diagram representing the genomic organization of MLV.  R, the repeat 
sequence; U5, unique 5’ sequence; PBS, the primer binding site; ψ, the encapsidation 
sequence; gag, gene encoding the viral structural proteins; pol, gene encoding the viral 
enzymatic proteins; env, gene encoding the viral envelope protein; PPT, poly purine tract; 
U3, unique 3’ sequence. 
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Retroviral genome 
 
 Retroviral particles contain two single-stranded RNA copies of their genome that 
form a dimer through self-complementarity at their 5’ ends [4].  Each monomer ranges 
from 7-13 kb in size.  The genome is transcribed using host cell machinery and therefore 
has many similarities to mRNA.  The genome has a 5’ cap and a poly [A] tail [5-7]. 
 
 The organization of most retroviral genomes is very similar (Figure 1-1B).  Many 
sequences within the genome play important roles in the virus life cycle. The R or repeat 
region is a sequence that is repeated on both the 5’ and the 3’ termini of the genome and 
is required for reverse transcription of the entire viral genome [8].  The U5 and U3 
regions stand for unique 5’ and unique 3’ sequences, respectively, and are critical for the 
provirus integration [9, 10].  Located downstream of the U5 is the PBS or primer binding 
site.  The PBS has specific interactions with host cell tRNA and is the site of initiation of 
reverse transcription [11, 12]. The ppt or polypurine tract, found on the 3’ end, is a run of 
nine or more A and G residues and is also a site of re-initiation of reverse transcription 
[13].  Downstream of the PBS is the ψ (Psi) sequence, which is responsible for the 
preferential encapsidation of the genome into the viral particle. 
 
   The genomes of all retroviruses contain a minimum of three genes which are 
termed gag (group specific antigen), pol (polymerase), and env (envelope protein).  The 
gag gene codes for capsid (Ca), nucelocapsid (NC), and matrix (MA) proteins, which are 
the structural proteins for the virus.  The pol gene encodes the enzymatic proteins, reverse 
transcriptase (RT), integrase (IN) and protease (PR).  The env gene codes for the viral 
envelope protein (Env) which covers the outside of the virus and is responsible for 
binding and membrane fusion with a host cell.        
 
 
Retroviral proteins 
 
 The structural proteins of a retrovirus are derived from the Gag polypeptide which 
is cleaved by the viral protease to yield MA, CA, and NC [14].   The MA protein forms 
an outer shell around the virus.  As the MA protein is translated it is modified by the 
addition of a myristic acid, a step which is key for proper retroviral assembly [15].  The 
modification targets the MA to the plasma membrane of the cell.  If this site is mutated 
particles will still assemble within the cytoplasm but will fail to make it to the plasma 
membrane [16].  The CA protein is conserved among many retroviruses and has a highly 
conserved region termed the major homology region (MHR).  The function the MHR 
region is not well understood, although mutations in this region seem to affect virion 
assembly in some viruses [17, 18].  The capsid protein forms a shell around the 
condensed inner core of the virus which contains the genome and enzymes required for 
replication.  This inner core can either be spherical, cylindrical, or conical in structure 
depending on the virus [2].  The NC protein is a small highly basic protein that has two 
copies of Cys-His motif.  These sequences fold around Zn2+ molecules forming a 
structure known as zinc fingers or zinc knuckles.  The NC protein binds tightly to the 
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viral genome [19] and may have roles in genome encapsidation as well as annealing the 
primer tRNA [2, 20]. 
 
 All retroviruses carry with them the three enzymatic proteins RT, IN, and PR 
[21].  RT has two enzymatic active sites, both are required for replication [3].  The first is 
an RNA-dependent DNA polymerase which reverse transcribes the viral genome into a 
DNA copy that can then be integrated into the host genome.  RT is a low fidelity 
polymerase with no proofreading function and therefore leads to a high error rate during 
viral replication [22].  This error rate allows viral populations to evolve rapidly in the 
host cell environment, as well as acquire resistance to drugs designed to block their 
replication [23, 24].  The second enzymatic site within RT is termed ribonuclease H 
(RNase H).  Its nuclease activity is specific for the RNA strand in an RNA:DNA hybrid 
[25].  The function of RNase H is to degrade the viral RNA genome as the DNA copy is 
being generated, creating short RNA primers used by RT to complete the replication 
process.  The IN and PR also play important roles in the replication process.  IN catalyzes 
important steps in the integration reaction by integrating the double-stranded viral cDNA 
into host cell chromosomal DNA where it is then referred to as the provirus.  The role of 
PR is to cleave the Gag polyprotein into the smaller protein products found in the mature 
virion [26].  Deletion of the sequences encoding PR from the pol gene result in non-
infectious particles with unprocessed Gag [27]. 
 
 The viral Env protein covers the outside of the virus.  It is comprised of two 
virally encoded subunits termed surface protein (SU) and transmembrane protein (TM) 
that are anchored in the lipid bilayer derived from the host cell (Figure 1-2).  These two 
subunits form an interaction through disulfide bonds or non-covalent bonds.  Unlike Gag 
and Pol the Env protein contains a signal peptide that targets it for translation in the 
endoplasmic reticulum (ER).  Within the ER the Env becomes glycosylated, folds, and 
assembles into oligomeric structures (mainly trimers) [3, 28].  The amount of 
glycosylation Env differs greatly between different retroviruses.  HIV-1 Env as 
approximately 30 glycosylation sites where as the MLV Env have less then 10 [3].  Env 
continues along the secretory pathway to the Golgi where it is cleaved to separate SU 
from TM and free the amino-terminus of the fusion peptide [29-31].   SU allows the virus 
to bind the host cell and the TM acts to anchor the protein to the virus and mediates the 
membrane fusion with the host cell membrane. 
 
 
Classification 
  
 Initially retroviruses were classified by the morphology of the virion core as 
visualized by electron microscopy.  These former classifications have now been 
expanded and new criteria have been added.  The Retroviridae family now consists of 
seven different genera:  Alpharetrovirus, Betaretrovirus, Gammaretrovirus, 
Deltaretrovirus, Epsilonretrovirus, Lentivirus, and Spumavirus.  These seven genera are 
divided into two groups of retroviruses, simple and complex.  Alpha, Beta, and 
Gammaretroviruses are considered simple retroviruses because they encode only the Gag, 
Pro, Pol, and Env gene products.  Deltaretroviruses, Epsilonretroviruses, Lentiviruses,  
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Figure 1-2.  Schematic representation of the MoMLV envelope protein.  The top 
represents a portion of the MoMLV particle that contains the surface protein (SU) and the 
transmembrane (TM) protein.  The bottom is a schematic representation of the two 
subunits SU and TM.   
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and Spumaviruses are considered complex retroviruses.  They code for the gag, pol, pro, 
and  env genes as in simple retroviruses but they also encode many other additional 
proteins that have a range of different functions, particularly regulatory and virulence 
proteins. 
 
 
Retrovirus life cycle 
 
 Receptor binding is the first step in a retroviral infection.  The viral SU protein 
binds a protein on the cellular surface.  Next, membrane fusion occurs; this is a mixing of 
the viral membrane with the cellular membrane.  This step is catalyzed by the viral TM.  
Membrane fusion can occur at the cell surface or internally with an endocytic vesicle.  
After the viral core enters the cytoplasm, uncoating of the capsid protein takes place and 
reverse transcription of the viral genome begins.   
 
There are approximately 50-100 molecules of RT per virion.  RT has two 
domains.  The first contains an RNA-dependent DNA polymerase activity which 
catalyzes reverse transcription of the RNA genome.  The second domain contains 
RNaseH activity, which degrades the RNA genome as it is being reverse transcribed into 
DNA.  Reverse transcription takes place in a complex made up of proteins including NC, 
RT, IN, and the viral RNA [32].  Like other polymerases RT cannot initiate transcription 
de novo; it requires a primer.  The RTs of all retroviruses use host cell tRNAs to prime 
the reverse transcription step.   
 
 The viral cDNA must gain entry to the nucleus.  This occurs via two mechanisms 
depending on the virus.  The first mechanism used by most simple retroviruses is to wait 
for nuclear envelope break down during mitosis [33, 34].  The second mechanism which 
is used by lentiviruses and spumaviruses appears to be an active transport method across 
the nuclear membrane [33, 35].  After entry into the nucleus by one of these two methods 
the linear viral cDNA is integrated into the host cell chromosomal DNA.   
 
 The U3 region of the provirus contains a promoter recognized by the cellular 
RNA polymerase II system.  Full-length viral transcripts generated by cellular RNA 
Polymerase II have several fates.  Some are packaged into the progeny virus to serve as 
the viral genome for the next round of infection.  Some are used for translation of Gag or 
Gag-Pol polyproteins.  Others are spliced to yield a population of sub-genomic mRNAs.  
In simple retroviruses this alternatively spliced product codes for the viral Env.  In 
complex retroviruses there can be multiple splicing events leading to the production of 
Env as well as other accessory proteins.   
 
 After transcription of the viral genome and translation of the viral proteins, the next 
step is assembly and budding of the virus particles.  The site of particle assembly varies 
depending on the genus of retrovirus.  The immature Gag proteins come together to form 
virus particles.  Full length retroviral genome is recruited into the particle.  These particles 
bud from the cellular membrane and their capsid becomes cleaved into a mature form by the 
viral protease.  Upon this maturation the virus is ready to infect a new host cell. 
7 
 
Chapter 2.  Cathepsin Cleavage of MoMLV Envelope 
 
 
Introduction  
 
 MLV are simple gammaretroviruses.  They can be divided into five different 
subgroups based on host range: amphotropic, ecotropic, xenotropic, polytropic and dual-
tropic [36]. Moloney murine leukemia virus (MoMLV) is an ecotropic MLV that is used 
as a model in retroviral replication and as a vector for gene therapy.  Despite extensive 
investigation there are still unanswered questions about early steps in this virus’s life 
cycle, including the membrane fusion step. 
 
 Infection of enveloped viruses involves attachment to cell surface receptors 
followed by fusion with cellular membranes to release the viral nucleocapsids into the 
cytoplasm [37, 38]. Receptor binding and low pH are known to be the two principal 
triggering mechanisms responsible for conformational changes in the retroviral Env 
which leads to the fusion event.  For pH-dependent viruses like mouse mammary tumor 
virus (MMTV) fusion occurs in an endocytic vesicle where these viruses encounter low 
pH (5.3-6.5) that induces  rearrangement in the viral Env and drive viral-cell fusion [37, 
39]. Entry into the endocytic pathway can be achieved by different routes including 
macropinocytosis, phagocytosis, clathrin- and caveolae-mediated pathways and some 
less-well defined routes called non-clathrin-, non-caveolae-dependent pathways [40].  
Most retroviruses including HIV-1 and HTLV-1 are pH-independent [41, 42].  Receptor 
binding in pH-independent retroviruses causes structural changes in the Env and allows 
fusion at neutral pH with the plasma membrane. 
 
 In many cell types including SC-1 and NIH 3T3, receptor-bound MoMLV is 
endocytosed and infection is blocked by the weak base NH4Cl [42, 43].  NH4Cl raises the 
pH in cellular compartments and is a classic way to test for pH-dependence.  So initially 
it appeared that MoMLV was pH-dependant.  However, several pieces of evidence now 
point towards the idea that cellular proteases may have a key role in viral fusion.  First, 
Klaus Andersen reported that MoMLV Env is cleaved upon virus entry [43] and that 
limited trypsin enhanced virus induced cell-cell fusion [44].  Second, although NH4Cl 
blocks infection in many cells types it does not do so in XC cells nor is it able to inhibit 
XC virus induced cell-cell fusion [42].  To explain this anomaly McClure and coworkers 
proposed that fusion was taking place at the cell surface aided by the secretion of a 
cellular protease that is normally found within the endosomal compartment [42].  This 
explanation turned out to be quite plausible.  XC cells are derived from a rat sarcoma 
induced by Rous sarcoma virus; they are a highly transformed cell line due to the 
expression of the viral src gene [45-47].  Viral-src-transformed cells have been shown to 
secrete cellular proteases such as cathepsin L [48, 49]. 
 
 Proteases belonging to the cathepsin family are best known for their role as 
lysosomal hydrolases.  Cathepsins are named using letters of the alphabet and are  
divided into three subgroups depending on which amino acid is present in the active site, 
cysteine (B, C, H, F, K, L, O, S, V, W, and X/Z), aspartate (D and E), and serine (G) 
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cathepsins [50].  Most cathepsins are endopeptidases while a few have exopeptidase 
activity as well.  In general, cathepsins are active at a low pH (5.0-6.0.)  Cathepsins are 
well known for their role in general protein turnover however recent works shows they 
also have roles outside the lysosomal compartment, i.e., degradation of extracellular 
matrix when secreted to the extracellular space and execution of programmed cell death 
when released to the cytosol [51, 52]. 
 
 Kumar et al., (2007) examined the role of cathepsin B in the life cycle of 
MoMLV.  They found that the cellular protease cathepsin B is important for MoMLV 
infection during membrane fusion and the best evidence suggested that it acts on the viral 
envelope protein [53].  Cathepsin B was able to cleave SU, but not TM or CA, into 
specific fragments.  When mouse embryonic fibroblasts (MEFs) derived from a cathepsin 
B knockout (B–/–) mouse were challenged with MoMLV they showed a decrease in 
infectivity when compared to B+/+ MEFs.  This suggested that cathepsin B plays a role 
during the infection.  However, the fact that infectivity was lowered and not abolished 
indicated that cathepsin B was important for infection but not critical.   
 
 One explanation is other cathepsins perform a similar or redundant function for 
MoMLV in the absence of cathepsin B.  Recent work on other viruses suggests that 
additional cathepsins could be involved during infection by cleavage of the viral 
glycoprotein.  Hendra and Nipah virus fusion (F) proteins are activated by cathepsin L 
cleavage within the endosomal compartment [54-56].  During Ebola virus infection 
cathepsin B is essential and cathepsin L plays an accessory role [57].  It has also been 
shown that cathepsin L cleaves the Ebola glycoprotein [58].  In severe acute  respiratory 
syndrome-coronavirus (SARS-CoV) inhibitors of cathepsin L inhibit infection [59] and 
SARS-CoV fusion protein is cleaved by cathepsin L [60].  Also feline enteric coronavirus 
(FECV) is highly dependent on cathepsin B and cathepsin L for entry into  host cells 
[61].  The involvement of other cathepsins in MoMLV fusion had not previously been 
tested.  The studies presented here investigate if other cysteinyl (cath B, K, L, S) and 
aspartyl (D) cathepsins cleave the MoMLV Env.  This work also highlights optimal 
conditions for in vitro digestion of MoMLV Env, as well as compares and contrasts 
products of the cleavage events.   
 
 
Materials and methods 
 
 
Cell lines 
 
 Mouse Fibroblast NIH 3T3 cells chronically infected with MoMLV were cultured 
in Dulbecco’s modified Eagle’s medium (DMEM; Cellgro) which was supplemented 
with 8% fetal calf serum (FBS; Sigma).  Cells were maintained at 37 ºC in 10% CO2. 
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Virus production 
 
 The virus used in these experiments was produced from NIH 3T3 cells 
chronically infected with MoMLV.  Viral supernatant was collected at 24, 48, and 72 hrs 
after cells reached 100% confluence.  Supernatant was then pooled and filtered through a 
0.45-µm filter.  The viral filtrate was pelleted by ultracentrifugation using a Beckman 
SW40 rotor at 30,000 rpm for 45 min at 4 oC.  Virus pellets were resuspended in 30 µl of 
ice cold PBS and stored at -80 ºC. 
  
 
Cathepsin digestion and western blot analysis 
 
  Reactions of 10 µl volume were assembled on ice in an acetate buffer (pH 5.5) 
and using MoMLV virus pellet and specified amounts of cathepsin B, D, K, L or S 
(Calbiochem).  In all cases, cathepsin K was activated prior to us following the 
manufacturer’s instructions.  The amount of virus pellet used was equivalent to an 
envelope protein band of 2 cm height after a 15 sec exposure of a western blot incubated 
with anti-gp70 antiserum.  The reaction was then incubated for 20 min at 37 ºC.  In some 
cases the reaction parameters for the cathepsin digestions varied.  The temperature was 
either 37 ºC or 4 ºC.  The amount of a cathepsin used varied from 0.185 mU to 1000 mU.  
The reaction time varied from 2 min to 100 min.  In order to limit the amount of digestion 
during a cathepsin B or cathepsin S digestion cathepsin S inhibitor (Calbiochem) was 
used at a concentration ranging from 0.1 µM to 100 µM.  Reactions were stopped by 
adding an equal volume of 2X gel loading buffer (1) and immediately heated to above 90 
ºC for 10 min. 
 
 After heating, samples were separated by SDS-PAGE through a 10-20% Tris-
glycine gel (Invitrogen) and transferred to a nitrocellulose membrane (Protran, Schleicher 
and Schuell).  The membrane was blocked for two hrs in 6% dry milk, 2% Tween 20 then 
incubated with goat anti-gp70 antiserum (Quality Biotech no. 80S000018; 1:100) for one 
hr. The primary antibody was detected by incubation with mouse anti-goat antibody 
conjugated to horseradish peroxidase (1:5,000) for 45 min followed by incubation with 
SuperSignal West Pico Chemiluminescent Substrate (Pierce).  After exposure membranes 
were stripped by incubation with Restore Western Blot Stripping Buffer (Pierce) 
according to the manufacturer’s protocol, with two exceptions. First, the incubation 
temperature was increased to 37 ˚C.  Second, the time of incubation was increased to 25 
min and including an additional 10 min at room temperature with constant rocking.  
Membranes were then reprobed for the capsid protein (CA) goat anti-p30 antiserum 
(Quality Biotech no. 80S000018; 1:100) for one hr and detected using the same 
secondary antibody as above. 
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Results 
 
 
Cathepsin B, D, K, L, and S cleavage of MoMLV envelope protein 
 
 In the following experiments purified cysteinyl cathepsin B, K L, S, or aspartyl 
cathepsin D were incubated with replication competent MoMLV under various 
conditions to investigate their cleavage ability on the SU and CA proteins.  Viral 
supernatant from NIH-3T3 cells was harvested and ultracentrifuged to purify replication 
competent MoMLV virions.  In vitro digestion by purified cathepsin was carried out 
using aliquots of pelleted MoMLV.  In a dose response to Cathepsin B the MoMLV SU 
was specifically cleaved but the CA remained intact (Figure 2-1).  These results agree 
with published data from Kumar et al, [53].  At 9.25 mU of cathepsin B, the SU was 
specifically cleaved yielding fragments that were 47, 35, and 28 kDa.  Increasing the 
amount of cathepsin B did not yield any new fragments but diminished the signal of the 
remaining protein. 
 
 In a dose response to cathepsin S, SU was specifically cleaved and CA was intact 
(Figure 2-2).  Low amounts of cathepsin S (lanes 3 and 4) specifically cleaved SU 
yielding fragments of 47 and 33 kDa.  At higher amounts of cathepsin S (lanes 5 and 6), 
these fragments became diminished and a 28 kDa fragment appeared.  The 28 kDa 
fragment remained resistant to cathepsin S cleavage until high amounts of cathepsin S 
were used (lane7).  At 50 mU of cathepsin S, the only signal detected was a small amount 
of intact SU. 
 
 In a dose response using cathepsin L the MoMLV SU was specifically cleaved 
and at high levels the CA signal was slightly diminished (Figure 2-3).  At 1.85 mU of 
cathepsin L (lane 4), the MoMLV SU was cleaved yielding fragments of 47 and 35 kDa.  
As the level of cathepsin L was increased to 9.25 mU the signal from the 47 and 35 kDa 
fragments became diminished and a 28 kDa fragment appeared.  At the highest dose of 
cathepsin L (lane 7), no protein could be detected.  Among all the cathepsins tested in this 
study, MoMLV SU showed the greatest sensitivity to cathepsin L.  Throughout the dose 
response the level of CA remains constant with the exception of the highest dose in 
which over half of the CA signal is gone (lane 7).   
 
 MoMLV was subjected to a dose response to cathepsin K ranging from 0.185 to 
50 mU and appeared no different than a no cathepsin control (data not shown).  However, 
using cathepsin K at levels 10-100 times that of the other cathepsins tested resulted in 
cleavage of SU (Figure 2-4).  When used at 100-500 mU cathepsin K was able to 
specifically cleave SU generating a 47 kDa band.  Using 1000 mU resulted in complete 
digestion of the 70 kDa SU and its products, leaving only a slightly detectable 28 kDa 
fragment.  The CA signal was reduced by over half when using this same dose.  
Cathepsin K does not appear to digest the SU at any biologically relevant level.    
  
 In a dose response to the aspartyl protease cathepsin D, the SU was specifically 
cleaved (Figure 2-5). Unlike cathepsin B, S, and L, cathepsin D digestion led to only one  
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Figure 2-1.  Dose response of cathepsin B cleavage on MoMLV SU.  Aliquots of 
MoMLV were incubated in acetate buffer (pH 5.5) with increasing amounts of cathepsin 
B for 1 hr at 37 ºC. Doses of cathepsin B from left to right were 0, 0.185, 9.25, 18.5, 25, 
37, 50 mU. Reaction products were separated via 10-20% SDS-PAGE and transferred to 
nitrocellulose membranes.  Membranes were incubated with anti-SU antiserum (top) then 
stripped and reprobed with anti-CA antiserum. 
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Figure 2-2.  Dose response of cathepsin S cleavage on MoMLV SU.  Aliquots of 
MoMLV were incubated in a pH 5.5 buffer with increasing amounts of cathepsin B for 
20 min at 37 ºC. Doses from left to right were 0, 0.185, 0.925, 1.85, 9.25, 18.5, 50 mU. 
Reaction products were separated via 10-20% SDS-PAGE and transferred to 
nitrocellulose membranes.  Membranes were incubated with anti-SU antiserum (top) then 
stripped and reprobed with anti-CA antiserum. 
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Figure 2-3.  Dose response of cathepsin L cleavage on MoMLV SU.  Aliquots of 
MoMLV were incubated in a pH 5.5 buffer with increasing amounts of cathepsin L for 20 
min at 37 ºC. Doses from left to right were 0, 0.185, 0.925, 1.85, 9.25, 18.5, 50 mU. 
Reaction products were separated via 10-20% SDS-PAGE and transferred to 
nitrocellulose membranes.  Membranes were incubated with anti-SU antiserum (top) then 
stripped and reprobed with anti-CA antiserum. 
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Figure 2-4.  Dose response of cathepsin K cleavage on MoMLV SU.  Aliquots of 
MoMLV were incubated in a pH 5.5 buffer with increasing amounts of cathepsin K for 
20 min at 37 ºC. Doses from left to right were 0, 50, 100, 500, 1000 mU. Reaction 
products were separated via 10-20% SDS-PAGE and transferred to nitrocellulose 
membranes.  Membranes were incubated with anti-SU antiserum (top) then stripped and 
reprobed with anti-CA antiserum. 
 
 
 
 
 
 
 
15 
 
  
 
 
 
 
 
 
 
    
 
 
Figure 2-5.  Dose response of cathepsin D cleavage on MoMLV SU.  Aliquots of 
MoMLV were incubated in a pH 5.5 buffer with increasing amounts of cathepsin D for 
20 min at 37 ºC. Doses from left to right were 0, 0.185, 0.925, 1.85, 9.25, 18.5, 50, and 
1000 mU.  Reaction products were separated via 10-20% SDS-PAGE and transferred to 
nitrocellulose membranes.  Membranes were incubated with anti-SU antiserum (top) then 
stripped and reprobed with anti-CA antiserum. 
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major fragment at 47 kDa. The other cathepsins displayed several major cleavage 
products.  Cathepsin D displayed a very low level of exopeptidase activity.  It was unable 
to cleave a significant amount of SU unless used at high levels.  To determine if the entire 
SU could be cleaved into the 47 kDa fragment, 1000 mU of cathepsin D was used  
(Figure 2-5, lane 8).  This did not result in a significantly higher amount of cleaved SU 
but instead diminished the signal of the 47 kDa product.   
 
 Cathepsins B, S, L, and D were able to cleave the MoMLV SU to some extent 
when used at low levels.  Direct comparison of digestion products from each cathepsin 
reaction were separated on the same gel (Figure 2-6).  Reactions were carried out at two 
different doses (1.85 mU and 9.25 mU).  All four cathepsins cleaved SU and generated a 
47 kDa band.  Cathepsin S and L shared identical cleavage patterns (47, 33, and 28 kDa).  
Digestion with cathepsin B yields only a slightly different banding pattern.   Instead of a 
33 kDa fragment a 37 kDa fragment.  MoMLV SU was more resistant to cathepsin D 
cleavage when compared to cathepsin B, S, and L.  It yielded only one product at 47 kDa 
and did so only at the higher dose. 
  
 
Controlling MoMLV Env digestion by temperature and inhibitors 
 
  It was possible that time could affect the digestion pattern.  To address this issue, 
a time course using 9.25 mU of cathepsin S at 37 ˚C was carried out (Figure 2-7).  Two 
observations came from this study.  First, the reaction was occurring very rapidly.  By the 
first time point, all the cleavage products were already formed.  Second, extended 
incubation time led to a decrease in signal from all fragments including SU.  Two 
approaches were used to limit the rate of the reaction so that the chronological 
appearance of the fragments could be investigated. The first approach was to slow the 
enzyme’s activity by lowering the reaction temperature.  A time course at 4 ºC using 9.25 
mU of cathepsin B resulted in the stepwise formation of the cleavage products seen in 
earlier digestions (Figure 2-8A).  This approach was useful for determining the order in 
which the cleavage products occurred and gave increased signal of these products.  Even 
after 100 min of incubation a large amount of protein remained (Figure 2-8B).  The 
second approach used Z-FL-COCHO, a reversible inhibitor of cathepsin B and S, to limit 
the enzymes activity.  Using a constant amount of cathepsin B or S (9.25 mU) and 
varying the amount of Z-FL-COCHO inhibitor allowed the sequential order of the 
fragments to be determined while maintaining larger amounts of the fragments       
(Figure 2-9 and Figure 2-10). 
 
 
Discussion 
 
 Cathepsins are emerging as key players in the entry mechanism of many different 
viruses including SARS-CoV, murine hepatitis virus, Ebola, Hendra, and Nipah [62].  
Cathepsins proteolytically cleave the viral glycoprotein which affects viral fusion [53-56, 
58, 60, 63].  Recent work in MoMLV indicated that cathepsin B is important for MoMLV  
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Figure 2-6.  Cathepsin digestion of MoMLV SU.  Aliquots of MoMLV were incubated 
in a pH 5.5 buffer with two doses of either cathepsin B, S, L, or D for 20 min at 37 ºC. 
Doses are 1.85 mU indicated by (+) or 9.25 mU indicated by (++).  Reaction products 
were separated via 10-20% SDS-PAGE and transferred to nitrocellulose membranes.  
Membranes were incubated with anti-SU antiserum (top) then stripped and reprobed with 
anti-CA antiserum. 
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Figure 2-7.  Cathepsin S digestion of MoMLV SU over time.  Aliquots of MoMLV 
were incubated in a pH 5.5 buffer with or without 9.25 mU of cathepsin S for 20, 40, or 
60, 80, 100 min at 4 ºC. Reaction products were separated via 10-20% SDS-PAGE and 
transferred to nitrocellulose membranes.  Membranes were incubated with anti-SU 
antiserum (top) then stripped and reprobed with anti-CA antiserum.   
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Figure 2-8.  Time course of MoMLV SU cathepsin S digestion at 4 ºC.  A) Aliquots of 
MoMLV were incubated in a pH 5.5 buffer with or without 9.25 mU of cathepsin S for 
20, 40, or 60 min at 4 ºC. Reaction products were separated via 10-20% SDS-PAGE and 
transferred to nitrocellulose membranes.  Membranes were incubated with anti-SU 
antiserum (top) then stripped and reprobed with anti-CA antiserum.  B)  Aliquots of 
MoMLV were incubated in a pH 5.5 buffer with 9.25 mU of cathepsin S for 100 min at 4 
ºC.  Products were then separated and probed using the same method as figure 3-8A.   
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Figure 2-9.  Cathepsin B digestion of MoMLV SU in the presence of cathepsin 
inhibitor.  Aliquots of MoMLV were incubated in a pH 5.5 buffer with or without 9.25 
mU of cathepsin S.  The cathepsin inhibitor, Z-FL-COCHO, was included in lanes 2-7 at 
levels of 1, 5, 10 25, and 100 µM respectively.   Reaction products were separated via 10-
20% SDS-PAGE and transferred to nitrocellulose membranes.  Membranes were 
incubated with anti-SU antiserum (top) then stripped and reprobed with anti-CA 
antiserum. 
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Figure 2-10.  Cathepsin S digestion of MoMLV SU in the presence of cathepsin 
inhibitor.  Aliquots of MoMLV were incubated in a pH 5.5 buffer with or without 9.25 
mU of cathepsin S.  The cathepsin inhibitor, Z-FL-COCHO, was included in lanes 2-7 at 
levels of 1, 5, 10 25, and 100 µM respectively.   Reaction products were separated via 10-
20% SDS-PAGE and transferred to nitrocellulose membranes.  Membranes were 
incubated with anti-SU antiserum (top) then stripped and reprobed with anti-CA 
antiserum. 
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infection during membrane fusion and that it cleaves the viral glycoprotein [53].  
However, in the absence of cathepsin B in KO cells, MoMLV infection is decreased and 
not blocked.  This lead to the hypothesis that other cathepsins may be involved by 
performing a redundant function in the absence of cathepsin B.  This is a likely scenario 
because the virus enters most cell types through the endosomal pathway, where it would 
encounter a variety of different cathepsins.  Being able to rely on more than one cathepsin 
could be a tremendous evolutionary advantage. 
 
 Together these results have shown that cysteinyl cathepsin B, S, L, and aspartyl 
cathepsin D are capable of cleaving MoMLV SU, while cleavage by cysteinyl cathepsin 
K required greater amounts of protease.  This means that the active site, which 
determines the class of the cathepsin, does not determine if cleavage of SU is possible.  
Cathepsins B, L, and D are ubiquitously expressed and located in the lysosomal 
compartment [64, 65].  Cathepsin S is also found in the lysosomal compartment of cells 
in many different  tissues including kidney, lymph nodes, lung, and spleen [66].  
Cathepsin K which has collagenolytic activity, plays a key role in bone resorption [67] 
and is expressed highly and preferentially in osteoclasts [65].  MoMLV enters through 
the lysosomal pathway, therefore it is likely to encounter cathepsins B, L, S, and D but 
not cathepsin K.  It is interesting that the cathepsins it probably encounters during 
infection are also the cathepsins most capable of cleaving SU. 
 
 Could the cleavage by cathepsins S, L, and D perform the same function as 
cathepsin B?  The digestion patterns of cathepsin S and L are nearly identical to that of B 
and the levels of enzyme at which this activity took place were similar.  Cathepsin B, L 
and S yield a cleavage product of 47 kDa, which is subsequently cleaved into a 28 kDa 
product.  They differ slightly in that cathepsin B has an intermediate product at 35 kDa 
and cathepsin S and L have an intermediate product at 33 kDa.  Given the similarities in 
the digestion patterns and activity it seems likely cathepsin S and L could function in the 
same manner as cathepsin B in MoMLV infection. 
 
 Cathepsin D generates an initial 47 kDa product but only at slightly higher 
concentrations then cathepsin B, L, and S.  At extremely high levels of cathepsin D the 
47 kDa band remains intact and is digested further.  Also a large population of the SU 
remains intact.  One explanation for the intact SU may be the heterogeneity of the 
population with respect to the level of glycosylation.  Given this heterogeneity, it is 
possible that the cleavage site of cathepsin D in SU could be masked on some molecules 
but not others.   
  
 Since the key cleavage site has not been identified, it cannot yet be determined if 
cathepsin D might provide a similar function in the absence of cathepsin B.  If the first 
cleavage product at 47 kDa is important to fusion, than cathepsin D could perform the 
same function as cathepsin B.  Cathepsin D appears to have a lower activity for SU 
cleavage than cathepsin B but the levels of cathepsin D that give the 47 kDa fragment are 
still within the physiological range observed in lysosomes.   
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 The cathepsins examined in this study should also be investigated for their role in 
fusion to provide evidence for their relevance of the observed digestion of SU.  When 
using the drug CA-074 Me during a MoMLV infection of NIH 3T3 cells, the amount of 
virus induced cell-cell fusion that occurs is reduced [53].  At low levels, CA-074 Me is an 
inhibitor of cathepsin B, at high levels it inhibits other cathepsins as well.  NIH 3T3 cells 
could be incubated with CA-074 Me to inactivate the amount of endogenous cathepsin 
present and then the inhibitor removed immediately prior to infection.  MoMLV could 
then be added to the cells in the presence or absence of the different cathepsins.  The 
affect of the cathepsins on cell-cell fusion could then be observed.  Cathepsins that 
restore cell-cell fusion would be inferred to have a role in the membrane fusion step of 
MoMLV infection. 
  
 Recent work indicates that cathepsin B may play a role in the membrane fusion 
step of MoMLV infection by cleaving the SU protein [53].  The current work shows that 
other lysosomal cathepsins are also able to cleave MoMLV SU.  Is the cleavage of SU 
important for the membrane fusion step?  If so, which sites are important?  The cleavage 
sites could be identified by digesting purified virus, removing the cathepsin digested 
fragments from an SDS-PAGE gel, and subjecting them to mass spectrometry and Edman 
degradation.  Using site directed mutagenesis these sites could be mutated, making them 
resistant to cleavage.  The importance of each site for membrane fusion could then be 
tested by infecting NIH 3T3 cells with the different cleavage mutants.  Mutants that 
display reduced or no fusion during infection would identify sites are important during 
membrane fusion and provide valuable information about the rearrangements of SU 
during the membrane fusion step of MoMLV infection. 
  
 Recently several enveloped viruses from different families were shown to be 
activated for fusion by cathepsin cleavage of their envelope glycoprotein, however the 
cleavage sites have not been determined. Identification of the cathepsin cleavage sites 
within MoMLV SU could be helpful in determining the mechanism of protease triggered 
fusion for the other enveloped viruses.  The location of the cleavage sites within the 
MoMLV SU structure should define new functional domains and give new insights into 
the mechanism triggering the envelope glycoprotein rearrangements that drive membrane 
fusion. If analogous domains exist in the other protease triggered viral glycoproteins then 
the mechanism revealed by MoMLV studies might be broadly applicable to 
understanding the protease trigger and structural rearrangements in the other enveloped 
viruses. 
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Chapter 3.  Deaminoacylation of Primer tRNAs by 
Retroviruses  
 
  
Introduction 
 
 Upon infection of a host cell the RNA genome is reverse transcribed into double 
stranded DNA, which then becomes integrated into the host cell genome [68, 69].  This 
process is mediated by the virally encoded enzyme reverse transcriptase (RT), which has 
RNA and DNA dependant DNA polymerase activity [68].  RT is found either in a 
monomer or in a dimer depending on the virus [4].  Similar to other polymerases, RT 
cannot initiate synthesis de novo, therefore a primer is required for reverse transcription 
to occur.  The RT of all retroviruses use host cell tRNA isoacceptors as primers to initiate 
transcription of the viral genome [11, 12].  Different retroviruses utilize different species 
of tRNA’s; Human immunodeficiency virus type 1 (HIV-1) and MMTV use tRNALys3, 
avian myeloblastosis virus (AMV) uses tRNATrp, and MLV uses tRNApro [70-75]. 
 
 
Recruitment of tRNA to retroviral virions 
 
Packaging of host cell tRNA takes place during the viral assembly process.  The 
amount and species of tRNA packaged varies greatly between viruses.  HIV, AMV, avian 
leukosis virus (ALV), Rous Sarcoma virus (RSV), and MMTV all selectively package 
their cognate primer tRNA [70, 76-80], while MLV does not show comparable levels of 
selectivity [78].  Despite all the interactions between the viral genome and primer tRNA, 
the viral genome does not appear to be involved in tRNA recruitment to the virion.  
Studies in MLV, HIV, and ASV have shown that in the production of viral particles that 
do not contain genomic RNA, tRNA profiles are the same as WT [74, 81].  A very 
interesting study was done in which three viruses were compared, HIV-1, RSV, (which 
both specifically recruit primer tRNA) and MLV.  Western blot analysis was performed 
on viral lysates to identify the presence of the three cognate synthetases, lysine (LysRS), 
tryptophan (TrpRS), and proline (ProRS).  HIV and RSV contained only LysRS and 
TrpRS respectively while MLV was negative for all three [82].  It appears that recruiting 
host cell aminoacyl-tRNA synthetase is a mechanism for specific tRNA recruitment.  
Using siRNA against LysRS leads to reduced packaging of tRNALys3, reduced annealing 
of primer to viral genome, and reduced viral infectivity of HIV-1 [83].        
                
The viral RT also seems to play a role in specific recruitment of primer tRNAs in 
certain retroviruses.  It has been shown through enzymatic digestion, chemical probes and 
cross-linking experiments that there are direct interactions between the TΨC and D loops, 
and the 3’terminus of tRNALys3 and HIV-1 RT [84-87].  In HIV-1, RSV and AMV, 
selective packaging is not observed in RT negative viruses [74, 88, 89].  Interestingly 
HIV-1 that is RT negative still contains LysRS but cannot specifically recruit tRNALys3 or 
place it on the viral genome [90].  This same involvement of RT does not seem to exist in 
MLV, a virus in which the primer tRNA is not heavily recruited.  A MLV mutant that 
was deleted for 40 % of its C-terminus showed only small differences in the amount of 
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tRNAPro present in the virion and had WT amounts of tRNAPro bound to the viral genome 
[91].  MLV mutants deleted completely for RT did show a reduction in the amount of 
free tRNAPro but still had WT amounts of the primer bound to the genome [91].  From 
these studies it seems that retroviruses that significantly recruit their primer tRNA do so 
through an interaction involving both their RT and the host cell aaRS.  MLV, a virus that 
does not share this same specific recruitment, does not require RT or the host cell aaRS to 
obtain and anneal its primer tRNA. 
 
 
tRNA interactions with viral genome 
 
The tRNA binds the eighteen nucleotides of its 3’ termini to a complementary 
sequence, the primer binding site (PBS), located in the 5’ untranslated leader region of 
the viral RNA genome [92].  The PBS is present in all retroviruses and is critical for 
replication. Viruses that contain mutations in which the eighteen nucleotide PBS is 
deleted, are non infectious [93].  Recently other sites having complimentarity between the 
tRNA and viral genome have been discovered.  These sites include the A-loop in HIV-1 
and the primer activation site (PAS) in HIV-1 and RSV [94, 95].  The A-loop region in 
HIV-1 is located just upstream of the PBS and is made up of four consecutive adenosine 
nucleotides that interact with the anticodon arm of tRNA Lys 3 [87].  Deletion of the A-
loop results in reduced replication kinetics and after many passages the sequence reverts 
back to WT [96].  The PAS, which has been characterized in HIV as well as RSV, is a 
small section of the viral genome upstream of the PBS which interacts with the TΨC loop 
of the primer tRNA [94, 95].  Deletion of the PAS does not decrease the amount of 
primer bound to the genome but reduces initiation, therefore lowering the amount of viral 
replication [95].  Phylogenetic analysis suggests that the PAS/tRNA interaction is 
possible in all retroviruses and may act as an underlying mechanism to regulate reverse 
transcription in retroviruses [97].  To summarize, the PBS binds the primer tRNA and is 
necessary for replication to occur, while the A-loop and PAS act once the primer is bound 
to regulate initiation of transcription.                                                                                                                   
 
 
Deaminoacylation 
 
One problem that all retroviruses must overcome in order to replicate is 
hydrolyzing the ester bond that is formed at the 3’ terminus when a tRNA isoacceptor is 
charged with an amino acid.  One way to overcome this is to bring tRNAs into the virion 
that are already deaminoacylated.  This would be very difficult to do because steady state 
cellular levels of tRNAs are almost always in the aminoacylated form [98].  There is also 
evidence to support the idea that the tRNAs going into the virion are in the aminoacylated 
state.  By making tRNALys3 anticodon mutants that differed in their ability to be 
aminoacylated, Kleiman’s lab was able to show a positive correlation between 
aminoacylation and incorporation into the virion [99].   
 
Deaminoacylation by RT has only been studied in two retroviruses, AMV and 
HIV-1.  The AMV RT enzyme was able to deaminoacylate tRNATrp, but only when the 
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tRNA was annealed to the genome [100].  This suggests that the complex formed 
between the AMV RT, genome, and primer places the RT in the correct position to 
perform the deaminoacylation step. HIV-1 and AMV are very similar in their recruitment 
mechanism of tRNAs to the virion, and the RT’s of these viruses have very specific  
interactions with their cognate primer tRNA [85, 101, 102].  It is likely that HIV-1 RT 
uses the same mechanism to deaminoacylate its primer tRNA.  Currently there has been 
only one study on the RT of HIV-1 to look for deaminoacylation activity in vitro.  The 
conclusion of this study was that RT did not substantially increase the rate of 
deaminoacylation [103].  However, this study was done using a very short segment of the 
HIV-1 genome, which failed to include the PAS site and therefore may not have been 
capable of forming the WT conformation best recognized by HIV-1 RT.  The 
experiments in the following study investigate the structure of HIV-1 RT for a logically 
placed hydrolase site. Then the deaminoacylation activity of HIV-1 RT is tested using a 
template that includes all the known interaction sites with the primer tRNALys3.  In 
addition, HIV-1 virions were examined for the presence of two proteins, histidine triad 
nucleotide-binding protein (HINT1) and human peptidyl-tRNA hydrolase 2 (Pth2), which 
could also attribute to deaminoacylation of tRNALys3. 
 
 
Materials and methods 
 
 
Construction and sub cloning of HIV-1 genomic segment  
 
 Polymerase chain reaction (PCR) was used to amplify nucleotides 1-652 of the 
HIV-1 genome from pLL3.7, a lentiviral expression plasmid (Invitrogen).  100 ng of the 
sense primer(5’ATAGGAATTCTACAATTAATACATAACCTTATGTATCATACAC 
ATAC GATTTAGGTGACACTATAGGTCTCTCTGGTTAGACCAG) and the 
antisense primer (5’ TGATCCCGGGCCTCTATCTTGTCTAAAGCTTC) were used in 
the reaction.  The sense primer contained a SP6 promoter site that would later be used for 
in vitro transcription.  Also within the primer sequence were EcoR I and Xma I restriction 
sites allowing for downstream subcloning.  Pfu DNA polymerase (Invitrogen) was used 
for high fidelity amplification.  PCR parameters were as follows; anneal at 68 ºC, extend 
at 72 ºC for 30 cycles.  The PCR product was purified using the QIAquick PCR 
purification kit (Qiagen) according to the protocol supplied by the manufacturer.  
Utilizing EcoR I and Xma I restriction sites contained in the primers, the 720 base pair 
fragment containing the HIV-1 genomic segment was subcloned into the E.coli 
expression vector pUC18 and then transformed into Top 10F’ E. coli.  Plasmid DNA was 
harvested from E. coli cultures grown under ampicillin selection using the Wizard plus 
Maxi prep kit (Promega) according to the protocol supplied by the manufacturer. Plasmid 
DNA was linearized using Xma I, treated with RNase A, to eliminate any residual RNA, 
then proteinase K digested and phenol/chloroform extracted.  This purified linear DNA 
was used as a template for in vitro transcription. 
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In vitro transcription of HIV-1 template 
 
 The linear DNA was in vitro transcribed and 5’ capped using MAXIscript 
(Ambion) and Cap Analog (Ambion) according to the protocol supplied by the 
manufacturer.  The product was then treated with DNase (Qiagen) to remove plasmid 
DNA.  The 652 nucleotide RNA product was verified by gel electrophoresis in a 
formaldehyde based running buffer [104] through a 0.8% agarose gel containing ethidium 
bromide.  
 
 
Crude purification of murine aminoacyl tRNA synthetase 
 
 Six livers from 14 week old B6 mice weighing 7.46 grams were mixed with 1.5 
volumes of cold cell lysis solution containing 10 mM Tris-HCl, 10 mM KCl, 2 mM 
MgCl2, 250 mM sucrose and 20 mM beta-mercaptoethanol.  The livers were then 
homogenized on ice and the solution was ultra-centrifuged in a SW40 rotor at 100,000 × 
g for 90 min.  The supernatant was loaded onto a DEAE cellulose column (30 ml bed 
volume) equilibrated with 0.05 M NaCl, 1 mM Na2 EDTA, 10 mM MgCl2.  The column 
was washed with 3 bed volumes of 0.25 M NaCl, 1 mM Na2 EDTA, 10 mM MgCl2 and 
eluted with 0.75 M NaCl, 1 mM Na2 EDTA, and 10 mM MgCl2.  Four ml fractions were 
collected and protein concentrations were determined by spectrophotometry.  Fractions 
with a protein concentration above 6 mg/ml were pooled. The final protein concentration 
of the pooled fractions was 11.75 mg/ml and frozen at -80 ºC. 
 
 
32P single nucleotide extension 
 
 HIV-1 genomic template (130 ng) was heat annealed to either 100 ng of a 
oligonucleotide complimentary to the PBS or 250 ng of purified tRNA using one of the 
three methods listed in Table 3-1.  Each of the reactions was then incubated with 0.5 µl of 
32P labeled dCTP [3000 Ci/mmol, 10mCi/ml (PerkinElmer)], 3 units of HIV-1 RT 
(Ambion) in a buffer containing 50 mM Tris-HCl (pH 8.3), 75 mM KCL, 3 mM MgCl2 
and 5 mM DTT.  Reaction was carried out at 37 ˚C for 45 min.  Aliquots (5 µl) of each 
sample were spotted on DE81 filter paper (Whatmann) and air dried.  Filters were 
washed five times for 5 min each in Na2HPO4 then twice in ethyl alcohol for 2 min and 
allowed to air dry.  Samples were placed in glass vials and mixed with 2 ml of H20.  The 
Cherenkov radiation was measured in a liquid scintillation counter. 
 
  
Aminoacylation assay and purification of tRNA 
 
 The crude murine synthetase preparation was used to aminoacylate tRNA with 14 
C lysine.  The reaction mixture contained 50 mM Tris-HCl (pH 7.5), 25 mM KCl, 10 mM 
MgCl2 , 5 mM ATP (pH 7.0), 20 mM BME, 0.4 mg crude murine synthetase preparation, 
1 mg of rabbit liver tRNA (gift from Dr. Katz), and 750 µM C-14 L-Lysine 322 
mCi/mMol (Perkin Elmer).   As a control, a duplicate reaction was set up but did not 
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Table  3-1.  Optimization of primer annealment to HIV-1 genomic template.  A)   
Heat annealing.   Each of the annealing protocols was tested by heat annealing the HIV-
1 genomic template to either a short DNA primer matching the PBS or purified tRNA.  
B)  32P-labeled single nucleotide extensions by HIV-1 RT.  Annealing reactions (3-1 
A) were extended using 32P-labeled dCTP by incubation with HIV-1 RT at 37 ˚C for 30 
min.  Aliquots of each reaction were spotted on DE81 filter paper and washed five times 
with Na2HPO4 (pH 7.5) then washed twice with ethyl alcohol.  Radioactivity was 
measured using a liquid scintillation counter in counts per minute (CPM). 
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A. 
 
Annealing protocol A Annealing protocol B Annealing protocol C 
 
30 mM Tris-HCl pH 7.5    
  20 mM EDTA             
600 mM NaCl 
 
 
30 mM Tris-HCl pH 7.5   
  20 mM EDTA            
   600 mM NaCl 
 
 
83 mM Tris-HCl pH 7.5     
125 mM KCl 
 
95 ˚C     3 min 
75 ˚C    30 min 
 
Return to room temp over 
45 min 
 
Ethyl alcohol precipitate / 
resuspend in H20 
 
95 ˚C    3 min 
 
 
Return to room temp over 
45 min 
 
Ethyl alcohol precipitate / 
resuspend in H20 
 
85 ˚C  3  min 
65 ˚C 10 min 
 
Return to room temp over 
45 min 
 
   
   
 
 
 
B. 
 
Annealing method (A, B, or C)  and primer used CPM 
 
                           (A)  No RT control  
 
1936 
RNA primer 2207 
DNA primer 14327 
  
                           (B)  No RT control 3810 
RNA primer  2600 
DNA primer 21576 
  
                           (C)  No RT control  2721 
RNA primer 3930 
DNA primer 
 
70100 
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contain protein from the synthetase preperation. Both reactions were incubated at 30 ºC 
for one hr.  To detect aminoacylation, 2 µl aliquots were spotted on GF/C filter paper 
(Whatmann) and immediately soaked in cold 10% TCA for ten min.  Filters were washed 
three times in cold 10% TCA and a final wash in cold absolute ethanol, all washes were 
10 min.  Filters were then dried and placed in Ecoscint XR scintillation solution (national 
diagnostics) and radioactivity was determined using a liquid scintillation counter.  Radio 
labeled aminoacyl-tRNA was purified by applying to a DEAE-cellulose column (3 ml 
bed volume).  Column and sample were equilibrated, washed, and eluted with the same 
buffers used in crude purification of murine Aminoacyl tRNA synthetase protocol 
described above.  The eluate (~8 ml) was mixed with 2.5 volumes ethyl alcohol, 
incubated 1 hr at -20 ºC and centrifuged at 3000 × g for 25 min.  Pellet was resuspended 
in 100 µl of Diethyl pyrocarbonate treated dH2O.  This radiolabeled tRNA could then be 
heat annealed to the HIV-1 genomic template.  
 
 
Annealing tRNA to HIV-1 genomic template 
 
 200 µg of C-14 aa-tRNA was incubated with 8 µg of HIV-1 genomic RNA 
template at 95 ºC for 2 min then placed on ice for 2 min. The reaction was then incubated 
at 75 ºC for 20 min in a buffer containing 20 mM KAc (pH 5.6). Next 5 mM MgCl2 was 
added and the reaction was allowed to return to room temperature. 
 
 
Deaminoaclyation assay of 14C-labeld tRNALys3 
 
 The annealed primer/template was mixed with a buffer to bring the final 
concentration of the reaction to 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2, 
and 5 mM DTT.  Either 25 units HIV-1 RT (Ambion) or AMV RT (NEB) was added and 
the mixture incubated at 37 ºC.  As a control, RT that had been heat inactivated for 30 
min at 95 ºC was added to a separate reaction.  Over time aliquots were removed and 
spotted on GF/C filter paper (Whatmann) and immediately soaked in cold 10% TCA for 
ten min.  Filters were washed three times in cold 10% TCA and a final wash in cold 
absolute ethanol, all washes were 10 min.  Filters were then dried and placed in Ecoscint 
XR scintillation solution (National Diagnostics) and radioactivity was measured using a 
liquid scintillation counter. 
 
 
RT-PCR of HIV-1 genomic template 
 
 One hundred ng of HIV-1 genomic transcript was reverse transcribed using 1 unit 
of HIV-1 RT (Ambion), 20 mM dNTPs (Invitrogen) in a buffer containing 50 mM Tris-
HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2 and 5 mM DTT.  Reaction was carried out 
using either 100 ng of an 18 nucleotide DNA primer matching the HIV-1 PBS or a 3 µg 
mixture of purified calf liver tRNA containing the natural primer tRNALys3 to test the 
HIV-1 genomic construct.  RT PCR parameters were 45 ˚C for 30 min.  Then DNA 
product was then amplified using PCR by adding 2.5 U of PFU Turbo DNA polymerase 
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(Stratagene), 20 mM fresh dNTPs, 100 ng of each primer U3 (5’ 
CTGGTTAGACCAGATCTGAGC) and the PBS (5’GTCCCTGTTCGGGCGCCA).  
PCR parameters were 95 ˚C for 2 min then 25 cycles (95 ˚C for 30 sec, 57 ˚C for 30 sec, 
72 ˚C for 1 min). The expected 192 base pair product was electrophoresed at 90 volts in a 
0.8% agarose gel containing ethidium bromide. 
 
 
Cell lysate 
 
 On  ice, 1 x 106 cells were incubated with cold NP-40 lysis buffer (1% NP-40, 50 
mM Tris [pH 8.8], 150 mM NaCl) containing protease inhibitor cocktail (1:25; Sigma P-
8340) for 20 minutes.  Cells were scraped off the dish and centrifuged (Eppendorf 5415C 
centrifuge) for 10 min , 4 °C, at 14,000 rpm to remove nuclei and cell. Lysates were 
treated with 10% SDS (0.1% [final]) and stored at -80 °C prior to SDS-PAGE separation.  
 
 
Western blot analysis of HINT1 and hPth2 
  
 Fifteen μl of 200 X recombinant HIV-1 virus pellet (gift from John Gray, St Jude 
Children’s Research Hospital), seven μl of 293 cell lysate, and seven μl of crude 
sythetase preperation (12 mg/ml) were mixed 1:1 with 2x loading buffer [104], boiled for 
10 min, chilled on ice, then electrophoresed through a 10-20% SDS polyacrylamide gel 
(Invitrogen) and transferred to a nitrocelluose membrane (Protran, Schleicher and 
Schuell).  The membrane was cut in half at the 15 kDa molecular mass marker, blocked 
for 2 hrs in 6% dry milk, and 2% Tween 20, then the top half was incubated for the 
histidine triad nucleotide binding protein 1 (HINT1) using mouse anti-HINT1 (1:1000, 
Genway), The bottom was probed for human peptidyl tRNA hydrolase 2 (hPth2 ) with 
chicken Affi-anti CGI-147 IgY (1:500 Abnova) over-night.  Primary antibody HINT1 
was detected by incubation with goat anti-mouse antibody conjugated to horseradish 
peroxidase (1:10,000) for 45 min followed by incubation with Super Signal West Pico 
Chemiluminescent Substrate (Pierce).  Primary antibody, Affi-anti CGI-147 IgY was 
detected by incubation with anti-chicken antibody conjugated to horseradish peroxidase 
(1:50,000) for 45 min followed by incubation with ECL Chemiluminescent Substrate 
(Amersham).   
 
 
Results 
 
 
Putative active site 
 To identify possible hydrolase sites on the RT enzyme the typical catalytic triad 
found in hydrolases (nucleophile [serine], an acid [aspartic acid], and a basic [histidine] 
residue [105]) served as a guide for what types of residues to identify.  To better 
understand the size and orientation of a hydrolase active site, the crystal structure of 
human Pth2 was analyzed [106].  AMV RT would have been the ideal protein to 
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investigate, given it is a RT that displays hydrolase activity, however the crystal structure 
has not been solved.  By examining the crystal structure of HIV-1 RT [107] in MBT 
[108], a practical hydrolase active site was located (Figure 3-1A).  The site contains the 
necessary catalytic residues (Serine, Aspartate, and Lysine) to form a possible active site.  
The residues are in the correct formation and distance apart (Figure 3-1B) when 
compared to the active site in hPth2.  A protein sequence alignment of HIV-1 RT 
(1HYS_A)and AMV RT [109] performed using Expasy illustrated that these same 
residues in HIV-1 RT were conserved in AMV RT (Figure 3-2).  Using the protein 
sequence alignment of the two enzymes a theoretical structure of AMV-RT was created 
using Swiss-Model and the same active site located (Figure 3-3).  Based on the computer-
generated model, the same three residues occur in a similar location to that of the HIV-1 
RT.  
 
Sub cloning and in vitro transcription of HIV-1 genomic segment 
 
 Polymerase chain reaction (PCR) was used to amplify nucleotides 1-652 of the 
HIV-1 genome from pLL3.7 a lentiviral expression plasmid.  This genomic template 
(Figure 3-4A) contains all of the known interactions between the tRNALys3 and the HIV-1 
genome.  Utilizing EcoR I and Xma I restriction sites contained in the primers, a 
fragment containing the HIV-1 genomic segment was cloned into the E.coli expression 
vector pUC18 and its identity confirmed by sequencing.  The SP6 RNA polymerase 
promoter site was also included in the primer design which resulted in the first nucleotide 
transcribed being nucleotide 1 of the HIV-1 genome.  Plasmid DNA was linearized using 
Xma 1 and the linear DNA was in vitro transcribed using the SP6 enzyme.  The RNA 
product 652 nucleotides long (Figure 3-4B) was verified by gel electrophoresis.  Due to 
the different properties between RNA and DNA, the transcript migrates slightly faster 
than expected when compared to the DNA size ladder.  To determine if the transcripts 
were indeed functional, they were tested in RT reactions using either a short DNA primer 
or tRNA primer matching the PBS (Figure 3-4C). 
 
 
Optimization of the heat-annealing method of primer tRNA association with a 
genomic template 
 
  Both the PBS contained within the U5 region of the HIV-1 genome and the tRNA 
possess large amounts of secondary structure [110, 111].  In order for priming to take 
place both the tRNA and the genomic template must undergo partial unfolding.  There 
are two established methods used to accomplish this unfolding.  The first is the use of the 
viral nucleocapsid [112], which  is thought to cause continuous melting and reannealing 
so that nucleic acids are able to undertake different conformations allowing them to find 
the most stable state [113].  The second mechanism for annealing tRNA to viral different 
conformations as they cool.  Maximum annealing is important due to the poor level of 
priming observed by tRNA when compared to short 18 bp DNA or RNA primers in vitro 
[114]. In order to increase the efficiency of future experiments it was important to   
optimize the annealing procedure. Three different annealing protocols were tried      
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Figure 3-1.  Potential hydrolase site in HIV-1 RT.  A) Crystal structure viewed in 
MBT Protein Workshop [115] of HIV-1 RT in complex with polypurine tract DNA:RNA 
template [107].  Potential hydrolase site residues are space filled and labeled.  B) Closer 
view of the HIV-1 RT, active site residues are red and space filled.  Catalytic triad of 
potential active site residues are purple, space filled, and distance between them 
measured in angstroms.   
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A. 
 
 
 
B. 
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HIV-1         65 KKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDESF 
AMV           63 KA-SGSYRLLHDLRAVNAKLVPFGAVQQGAPVLSALPRGWPLMVLDLKDACFFSIPLAEQD 
                 *  *   * * * *  *     *  ** * *    *       ***  *  ** ** *   
 
HIV-1        125 RKYTAFTIPSMNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEMVIYQYM 
AMV          122 REAFAFTLPSVNNQAPARRFQWKVLPQGMTCSPTICQLIVGQILEPLRLKHPSLRMLHYM 
                 *   *** ** **  *  * *  *****   ** * *     **** * * *      ** 
 
HIV-1        185 DDLYVGSDLEIGQHRTKIEELRAHLLRWGFT-TPDKKHQKEPPFLWMGYELHPDRWTVQP 
AMV          182 DDLLLAASSHDG-LEAAGEEVISTLERAGFTISPDKV-QREPGVQYLGYKL-GSTY-VAP 
                 ***        *      **    * * ***  ***  * **     ** *      * * 
 
 
Figure 3-2.  Sequence alignment of HIV-1 RT and AMV RT.  Protein sequence 
alignment of HIV-1 RT and AMV RT using EXpasy pairwise alignment program.  
Potential active site residues are indicated in red.   
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Figure 3-3.  Potential hydrolase site within model of AMV-RT.  Computer generated 
model of AMV RT created by Swiss Model and viewed in RasMac.  Polymerase active site 
residues are spaced filled and red, potential hydrolase active site residues are space filled 
and represented in green. 
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A. 
 
 
 
 
B.                                                        C. 
         
 
 
Figure 3-4.  652 nucleotide RNA transcript of HIV-1 genomic template.   A) 
Schematic of the RNA transcript produced by the SP6 enzyme.  It consists of 
nucleotides 1-652 of the HIV-1 genome (NC-001802) and contains the unique 3’ 
sequence (U3), the primer activation site (PAS), the A rich sequence (A-loop), the 
primer binding site (PBS) and approximately 330 nucleotides of the Gag 
polyprotein.  B) Gel electrophoresis of RNA prouduced from in vitro 
transcription reactions. Lanes A and B are 5 µl from 20 μl in vitro transcription 
reactions, lane C is 1 μg of DNA ladder.   Aliquots A and B were heated to 95 oC 
for 2 minutes then loaded onto a 0.8% agarose gel containing ethidium bromide.  
Samples were electrophoresed at 90 volts in a formaldehyde based running buffer.  
C)  RT-PCR of  the in vitro transcription product.  100 ng of HIV-1 genomic 
transcript were reverse transcribed by HIV-1 RT using either a 18 nucleotide 
DNA primer matching the PBS (lane A) or tRNALys3 (lane B).  DNA products 
were amplified by PCR using DNA primers matching the sequence in the U3 and 
the PBS.  The expected 192 base pair product was electrophoresed at 90 volts in a 
0.8% agarose gel containing ethidium bromide beside a 1 ug DNA ladder (lane 
C). 
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(Table 3.1A).  They were tested by measuring the amount radioactivity detected in 32P-
labeled dCTP single nucleotide extensions by HIV-1 RT (Table 3-1B).      
 
 
Crude purification of synthetases and aminoacylation of tRNA 
 
 There are 20 different Aminoacyl-tRNA synthetases (aaRS).  Each aaRS is 
capable of charging all of its cognate tRNAs and can discriminate from all other tRNAs 
with great efficiency [116].  In order to perform key deaminoacylation experiments with 
RT, tRNALys3 needed to be charged with 14C Lysine using the lysyl-tRNA synthetase 
(LysRS).  Synthetase proteins were partially purified from the livers of 14 week old B6 
mice.  Homogenate from the livers was ultracentrifuged and the supernatant was further 
purified based on charge using a DEAE cellulose column.  The column fractions were 
analyzed by spectrophotometry and fractions containing over 5 mg/ml were pooled 
(Figure 3-5).  To insure the crude synthetase preperation still maintained activity after the 
purification process it was tested by charging tRNA with 14C Lysine (Figure 3-6).  The 
reaction which contained the synthetase preperation yielded high levels of charged tRNA 
when compared to the same reaction which did not contain the synthetase preperation. 
 
 
Deaminoacylation of lys-tRNALys by HIV-1 RT and AMV RT 
 
 Based on the structural data it appeared that HIV-1 RT had a possible hydrolase 
site in the expected region.  The hypothesis that HIV-1 RT had  hydrolase activity was 
tested.   When 14C Lys-tRNALys that was heat annealed to the HIV-1 genomic template is 
incubated with HIV-1 RT, the loss of radioactivity observed is roughly equal to that of 
the heat inactivated control (Figure 3-7).  The decrease in radioactivity signifies the 
population which becomes deaminoacylated.  The control sample, which contains heat-
inactivated HIV-1 RT, represents the in vitro rate of the spontaneous deaminoacylation of 
14C Lys-tRNALys.  The presence of HIV-1 RT does not increase the deaminoacylation 
rate and therefore does not appear to have hydrolase activity.  However, the limitations of 
this assay permit any definitive conclusions.  The rate of spontaneous deaminoacylation  
of tRNALys in vitro observed in the control (Figure 3-7 and Figure 3-8) is very high.  It 
therefore possible that HIV-1 RT does have a low level of hydrolase activity but is being 
masked by the high level of spontaneous deaminoacylation. 
 
AMV RT on the other hand has been shown to contain hydrolase activity when 
incubated with its own genomic RNA annealed to 14C Trp-tRNATrp.  Is this hydrolase 
activity specific to its own primer tRNA or is it capable of hydrolyzing Lys-tRNALys3 as 
well?  To analyze this question, AMV RT was incubated with Lys-tRNALys that was heat 
annealed to the HIV-1 genomic template (Figure 3-8).  AMV RT, unlike many other RTs, 
is capable of initiating reverse transcriptase on an  HIV-1 genome using tRNALys as a  
primer [117].  However, based on the results of this experiment, it does not appear that 
AMV RT is capable of deaminoacylating Lys-tRNALys.  The rate of spontaneous 
deaminoacylation is high but is not increased with the addition of AMV RT. 
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Figure 3-5.  Collection of crude murine aminoacyl-tRNA synthetase.  20 ml of 
murine liver homogenate was ultra centrifuged at 100,000 × g for 90 min.  Supernatant 
was loaded onto a DEAE cellulose column.  Four ml fractions were collected and their 
absorbance at 280 nm was measured.  Fractions with high 280 nm absorbance, indicated 
by grey shaded region, were pooled together for aminoacylation reactions. 
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Figure 3-6.  Aminoacylation of rabbit tRNA lysine by crude murine aminoacyl-
tRNA synthetase.  Crude murine aminoacyl-tRNA synthetase preperation was tested for 
aminoacylation activity.   Two 400 ml reactions both containing 3 μCi of C-14 labeled 
lysine, and 1 mg of rabbit tRNA were set up.  The first reaction, indicated by the black 
bar, did not contain the aminoacyl-tRNA synthetase.  The second reaction, indicated by 
the grey bar, contained 0.4 mg of the aminoacyl-tRNA synthetase.  Both reactions were 
incubated at 30 ˚C for one hour.  2 μl from each reaction was spotted on whatman GF/C 
filter paper and soaked in cold 10%TCA (trichloroacetic acid).  Filters were washed in 
10% TCA and radioactivity counted using a liquid scintillation counter. 
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Figure 3-7.  Deacylation of 14C-labeled Lys-tRNALys by HIV-1 reverse transcriptase.  
50 µl reactions containing 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2, 5 mM 
DTT and 250 ng of HIV-1 genomic RNA template annealed with  14C Lys-tRNALys.  
Reactions either contained 25 U of HIV-1 RT or 25 U of heat inactivated HIV-1 RT.  
Reactions were incubated at 37 oC and stopped at various time points by the addition of 
cold 10 % TCA.  Aliquots were spotted onto nitrocellulose membranes, washed, and 
counted via liquid scintillation counter.     
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Figure 3-8.  Deacylation of 14C-labeled Lys-tRNALys by AMV reverse transcriptase.  
50 µl reactions containing 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2, 5 mM 
DTT and 250 ng of HIV-1 genomic RNA template annealed with  14C Lys-tRNALys.  
Reactions were carried out either +/- 25 U of AMV RT.  Reactions were incubated at 37 
oC and stopped at various time points by the addition of cold 10 % TCA.  Aliquots were 
spotted onto nitrocellulose membranes, washed, and counted via liquid scintillation 
counter.     
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Detection of cellular proteins within recombinant HIV-1 
 
 An alternative possibility for deaminoacylation of the HIV-1 primer tRNA could 
cellular proteins.  I examined the possibility that a cellular protein may be recruited into 
the virion to carry out this function.  Based on the literature, HINT1 and hPth2 were two 
candidate of cellular proteins that may have roles in the aminoacylation and 
deaminoacylation process.  HINT1 is a cellular protein which has an array of functions 
including interaction with LysRS to form charged Lys-tRNALys [118].  Its role is to 
hydrolyze the AMP that is linked to lysine during the first step of the charging reaction.  
To determine the presence of HINT1 in recombinant HIV-1 (gift from John Gray), the 
virus was lysed and incubated using antibodies specific for HINT 1 (Figure 3-9).  The 
result was that the 13.9 kDa HINT1 was not present in the HIV-1 recombinant pellet but 
was present in the positive controls, which were lysate from a 293 cell line and protein 
from the crude murine synthetase preperation.  
 
 hPth2, also called Bcl-2 inhibitor of transcription 1 (Bit1), displays excellent 
hydrolase activity against Lys-tRNALys [106].  It plays a critical role in cellular protein 
synthesis by freeing up tRNA that is bound to proteins which have not been fully 
translated [119].  Given this proteins ability to hydrolyze the bond between a tRNA and 
its amino acid chain, it was an excellent candidate for deaminoacylation of the primer 
tRNA within HIV-1.  Its presence was confirmed by performing western blot analysis on 
the recombinant HIV-1 pellet with antibodies specific to hPth2 (Figure 3-10). 
 
 
Discussion 
 
 
Retroviruses evolved different mechanisms to obtain deaminoacylated primer 
tRNAs 
 
 Given the intense interaction between HIV-1 RT with tRNALys during recruitment 
[84-87] and the evidence that AMV RT deaminoacylates its primer tRNA [100], HIV-1 
RT seemed a very likely candidate to carry out the deaminoacylation step.  Examination 
of its crystal structure led to the identification of a possible hydrolase site.  When the 
catalytic activity of this site was tested, the evidence showed that HIV-1 RT did not 
increase the rate of deaminoacylation over that of the rate of spontaneous 
deaminoacylation. I interpret this result to indicate that HIV-1 RT was not capable of 
deaminoacylating its primer tRNA at a rate that exceeds spontaneous loss of the amino 
acid.  AMV RT is able to deaminoacylate 50% of trp-tRNATrp within 10 min [100].  If 
HIV-1 RT were able to deaminoacylate its primer tRNA at a rate similar to AMV RT we 
would expect to observe a decrease in the total amount of radioactivity that exceeded the 
spontaneous loss.  A decrease would be most apparent at the later time points when 
compared to the control.  However, the total amount of acid-precipitable radioactivity is 
the same as the control after 15 minutes (Figure 3.7).  I interpret this as evidence that 
HIV-1 probably uses an alternative mechanism to deaminoacylate tRNALys3.  The use of 
another mechanism by HIV-1 would indicate that retroviruses have evolved different 
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Figure 3-9.  Absence of HINT1 from recombinant HIV-1.  Samples were separated via 
10-20% SDS-PAGE and transferred to a nitrocellulose a membrane.  Membrane was 
incubated with HINT1 polyclonal antibody. 
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Figure 3-10.  hPTH2 in recombinant HIV-1 virions.  Samples were separated via 10-
20% SDS-PAGE and transferred to a nitrocellulose a membrane.  Membrane was 
incubated with Affi-anti CGI-147 IgY antibody. 
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ways to accomplish this common goal of primer deaminoacylation.  These results, 
however, do not rule out the possibility that HIV-1 RT has a low level of hydrolase 
activity towards tRNALys3.  To better understand the process of primer deaminoacylation 
by retroviruses further experiments should be carried out.  The sensitivity of the assay 
needs to be improved, specifically by achieving a lower level of spontaneous 
deaminoacylation of lys-tRNALys.  This could be accomplished by lowering the pH of the 
reaction.  Multiple reactions could be set up, each one having a slightly lower pH then the 
other.  It should be noted that going below a certain pH will inactivate the HIV-1 
polymerase activity and might similarly inhibit the hydrolase activity.   
 
Currently, the mechanism for deaminoacylation of tRNAPro by MoMLV is 
unknown.  Since deaminoacyation by the AMV RT enzyme is the only established 
mechanism, it remains the most likely candidate in other retroviruses as well.  Similar   
experiments could be carried out using the RT of MoMLV.  MoMLV genomic RNA 
could be harvested from virus productions.  Purified tRNA, 14C-labeled proline, and 
purified MoMLV RT are commercially available.  Using protocols described in this 
chapter MoMLV RT could be tested to determine its ability to deaminoacylate its primer 
tRNA.  Other aa-tRNAs have shown lower in vitro rates of spontaneous 
deaminoacylation then Lys-tRNALys displayed.  Therefore, this assay may be more 
sensitive when using different aa-tRNAs. 
 
 
AMV-RT shows specificity towards tRNATrp                                                                 
 
 Specific conformations and interactions occur between tRNALys3, the HIV-1 
genome, RT, and nucleocapsid, which allow priming and initiation of reverse 
transcription to take place [117, 120-122].  It has been shown that AMV RT, unlike many 
other retroviral RTs (including FIV, EIAV and MLV), is capable of initiating reverse 
transcription of the HIV-1 genome using its cognate primer tRNALys3.  However, AMV 
RT was not able to increase the rate of deaminoacylation over the background levels of 
spontaneous deaminoacylation of noncognate tRNALys.  The rate of deaminoacylation of 
the cognate tRNATrp by AMV RT is about 50 % in 15 min [100]. Given this high rate, if 
AMV RT were capable of recognizing tRNALys as efficiently as its cognate tRNA, a 
higher level of deaminoacylation would be observed in the presence of RT.  From the 
data, it appears thus far that the hydrolase activity demonstrated by AMV RT is specific 
to tRNATrp.  This study was limited in that it only tested AMV RT’s ability to prime one 
other retroviral genome.  AMV can only deaminoacylate its own primer tRNA when the 
tRNA is bound to the genome.  Due to the specific conformations formed when a tRNA 
interacts with a retroviral genome it would be interesting to determine if AMV RT could 
deaminoacylate its cognate tRNA when it is bound to a foreign genome.  To test this, the 
genomes of other avian viruses including Rous sarcoma virus would be used; it utilizes 
the same primer as AMV.  14C-Trp-tRNATrp would be heat annealed to this genome and 
incubated with AMV RT.  The rate of deaminoacylation would be compared to the same 
reaction containing heat inactivated AMV-RT.  The data gained from this experiment 
would provide information about the influence of interactions between tRNATrp and a 
different genome on deaminoacylation.  If the interactions sites between the genome and 
47 
 
tRNATrp are similar, the orientation of AMV RT should also be similar and therefore be 
able to deaminoacylate the primer.  However, if there are alternate interaction sites 
between the genome and primer, this could change the conformation of the entire 
RT:genome:tRNA complex and therefore AMV RT would most likely not be able to 
deaminoacylate tRNATrp.  
 
 
The presence and absence of cellular proteins from recombinant HIV-1 
 
 The absence of HINT1 from HIV-1 lentiviral vectors suggests that it does not 
play a role in the deaminoacylation process within the virion.  Its absence however does 
provide other clues to the recruitment of LysRS into the HIV-1 virion.  Many labs have 
shown recruitment of LysRS to the HIV-1 virion but the origin and type of LysRS 
remains a heated debate.  There are two forms of LysRS, a mitochondrial and a 
cytoplasmic, that result from an alternative splice of the same gene [158].  The two forms 
which share 576 identical amino acid residues differ only at their amino terminus [124, 
159].  The LysRS present in virions does not seem to originate from any of the identified 
steady-state cellular compartments, which include the cytoplasmic high molecular weight 
aaRS complex, nuclei, and cell membrane [83, 123].  Some investigators believe the 
source to be the mitochondrial form [124] while others believe newly synthesized LysRS 
[123] is the source.  Recently HINT1 has been isolated from complexes containing 
LysRS and appears to function  in part to regulate the catalytic activity of LysRS [118].  
Given their close interaction, both physically and chemically, it is likely that many forms 
of the LysRS would be found in association with HINT1.  The absence of HINT1 from 
HIV-1 virions may provide clues as to which source of LysRS the virus recruits.  By 
isolating and testing the different sources of LysRS it would be possible to determine 
which sources are associated with HINT1.  The sources of LysRS that do not contain 
HINT1 will probably not be recruited by HIV-1. 
 
 The presence of hPth2 with the recombinant HIV-1 virion is very exciting.  The 
role of this protein within HIV-1 is currently unknown.  Due to its cellular function, it 
instantly becomes a candidate in the role of deaminoacylation of the primer tRNALys3.  
Given the nature of retroviruses, it is possible that this protein is not specifically recruited 
but simply taken up by the virus as it buds from the cell and may have absolutely no role 
in viral replication.  The low levels detected within the virion seem to suggest this may 
indeed be the case.  To examine if hPth2  has any role in HIV-1 replication, HIV-1 
should be produced from cells containing reduced amounts of hPth2.  To accomplish this 
siRNAs directed against hPth2 could be used.  Western blot analysis of these cells would 
be needed to determine if the siRNA effectively downregulated hPth2.  HIV-1 could be 
produced from these cells and its infectivity compared to that of HIV-1 produced from 
hPth2 positive cells. 
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Chapter 4.  Increasing MoMLV Envelope Gene Expression 
 
 
Introduction 
 
 One method of producing recombinant replication deficient MoMLV is the three-
plasmid system.  The gag and pol genes are expressed from the pcDNA-MoMLV 
Gag/Pol plasmid and env gene is expressed from the pcDNA-MoMLV Env plasmid.  
These plasmids are provided exogenously through transient transfection.  The third 
plasmid, which acts as the viral genome, is provided from within the cell.  The producer 
cell line, termed H1-BAG, is a human embryonic kidney 293 cell line that contains an 
integrated copy of the pBAG plasmid [125]. This plasmid contains the LacZ gene under 
the control of the viral 5’ LTR and contains the psi sequence. The presence of psi marks 
the transcript for viral packaging and allows the transcript to act as a viral genome.  This 
system produces recombinant MoMLV that is capable of a single round of infection only. 
  
 In MoMLV, as well as all other retroviruses, alternative splicing of the genomic 
mRNA produces the Env transcript.  This subgenomic mRNA codes for Env but does not 
contain the coding sequences for Gag, Pro, or Pol.  The ratio between full length genomic 
mRNA and the spliced Env mRNA is approximately 2:1, respectively [126].  One 
outcome of using the three plasmid system was that the ratio of pcDNA MoMLV 
Gag/Pol to pcDNA-MoMLV Env was not 2:1 as expected.  Much greater amounts of the 
pcDNA-MoMLV Env were needed for transfection than was predicted.  To address this 
problem the nucleotide sequence of pcDNA-MoMLV Env was analyzed. The sequence 
contained the viral splice donor (SD), splice acceptor (SA), and three short open reading 
frames (ORFs).  The presence of the SD, SA, and ORFs suggested two hypotheses.  The 
first was the short ORFs were somehow distracting or stalling the ribosomes during 
scanning so that many ribosomes released the mRNA prematurely, resulting in reduced 
Env expression.  The second was that the Env mRNA was not being spliced efficiently, 
thereby trapping the mRNA in the nucleus and leading to reduced Env expression.   
  
 The AUG codon marks the beginning of an ORF and serves as the start codon to 
initiate translation.  Translation efficiency of a gene depends upon the context of the 
AUG start codon.  In eukaryotic cells, selection of the appropriate AUG codon is 
facilitated by the presence of a Kozak sequence: 5’ RNNAUGR 3’, where R denotes a 
purine and N denotes any nucleotide.  Of the three upstream ORFs found in pcDNA-
MoMLV Env, ORF 1 and 2 (designated by their position relative to the 5’ end), are not in 
a Kozak consensus sequence and are not in the same reading frame.  The 3rd ORF is in 
the correct reading frame and contained an optimal Kozak sequence.  It was reasoned that 
the first two upstream ORFs may be distracting ribosomes by attracting them to the 
incorrect translation initiation site or stalling the ribosomes leading to a decrease in the 
amount of protein produced from these transcripts.  This hypothesis is supported by the 
finding, that elimination of upstream AUG sites, not in Kozak consensus, increased gene 
expression in retroviral vectors [127].  It is possible the 3rd ORF is being translated but it 
is unknown if the protein produced from this site is stable or goes in virions.  Therefore, 
the presence of the 3rd ORF could also be inhibiting the optimal expression of pcDNA-
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MoMLV Env.  To evaluate this hypothesis, mutations in pcDNA-MoMLV Env were 
made which eliminated the three upstream ORFs.  Env expression and viral infectivity 
were examined in recombinant MoMLV produced using these mutants. 
 
 An alternative hypothesis is that a reduced amount of message in the cytoplasm 
available for translation is due to inefficient splicing and nuclear export of Env mRNA.  
Splicing of pre-mRNA is tied to nuclear export [128].  Many of the proteins responsible 
for splicing are also involved in nuclear export pathways [129-132].  The presence of a 
SD and SA in pcDNA-MoMLV Env should therefore increase the amount of mRNA in 
the cytoplasm and increase the amount of Env expression.  However, the natural SD and 
SA sequence present in MoMLV, and therefore pcDNA-MoMLV Env, do not match the 
consensus sequence necessary for efficient splicing.  Early studies in avian retroviruses 
proved that this was a strategy employed by these viruses as a way to regulate alternative 
splicing and maintain the proper balance between genomic and subgenomic mRNAs 
[133].   Mutations to SA that improved splicing efficiency, resulted in reduced viral 
replication due to the lack of full length transcripts [126].  Given that splicing is 
important for nuclear export, it was reasoned that many of the pcDNA-MoMLV Env 
transcripts were not being exported from the nucleus and therefore not being translated.  
To examine this possibility the SD and SA sequences were mutated to improve or inhibit 
the splicing.  The effects of the mutations on envelope protein expression and viral 
infectivity in recombinant MoMLV were examined in the following experiments.  
 
 
Materials and methods 
 
 
Cell lines 
 
 Human 293 embryonic kidney cells and mouse NIH 3T3 fibroblasts were 
maintained in DMEM containing 8% donor calf serum.  The packaging cell line H1-BAG 
(293 cells stably expressing recombinant MoMLV BAG genome encodes the beta-
galactosidase gene) [125] was maintained in DMEM containing 8% fetal bovine serum 
(FBS) and 250 µg of G418/ml. 
 
 
Plasmid construction 
 
 Plasmid pcDNA-MoMLV Env containing only the envelope [134] was used as 
the backbone to create variations in the 5’ untranslated region.  Specific point mutations 
were made using oligonucleotide-directed mutagenesis with the primers listed in Table 4-
1.  Primer pairs that contained a 5’ phosphate group were used in conjunction with the 
ExSite kit (Stratagene) according to the manufacturer’s protocol with the exception of the 
PCR parameters which are described in this section.  All other mutations were performed 
using the QuikChange kit (Stratagene) according to the manufacturer’s protocol. 
 
 
50 
 
 
 
 
 
 
 
 
 
 
 
Table 4-1.  Oligonucleotides used for mutagenesis.  
 
Oligonucleotide Nucleotide sequence 
 
ORF 1-fwd 
 
5’-GGAGGTAAGCTGGGCTATCGGATCTTATATGGGGCACCC-3’ 
ORF1-rev 5’-GGGTGCCCCATATAAGATCCGATAGCCCAGCTTACCTCC -3’ 
ORF1+2-fwd 5’-CACCACCGGGAGGTAAGCTGGGCTATCCGATCTTATACAGGGCACCCCCGCCCC 
     TTGTAAACTTCCCTGAC-3’ 
ORF1+2-rev   5’-GTCAGGGAAGTTTACAAGGGGCGGGGGTGCCCTGTATAAGATCGGATAGCCCAG 
      CTTACCTCCCGGTGGTG-3’ 
ORF3-fwd 5’-CCTTGTAAACTTCCCTGACCCTGACTGTACAAGAGTTACTAACAGCCCCTCTC-3’ 
ORF3-rev 5’-GAGAGGGGCTGTTAGTAACTCTTGTACAGTCAGGGTCAGGGAAGTTTACAAGG-3’ 
p-Splice Donor-
fwd 
5’-GACCACCGACCCACCACCTGCAGGTAAGCTGGGCTATGAG-3’ 
p-Splice Donor-
rev 
5’-CTCATAGCCCAGCTTACCTGCAGGTGGTGGGTCGGTGGTC-3’ 
p-Splice acceptor-
fwd 
5’-Phosphate-TCTCTCCTCTCTGCAGGTCACTTACAGGCTCTCTACTTAGTCC-3’ 
p-Splice acceptor-
rev 
5’-Phosphate-GTTAGTAACTCTTGTCATGTCAGGG-3’ 
SA fix-fwd 5’-Phosphate-GACATGACAAGAGTTACTAACTTCTTCCCCTCTCTGCAGGTCAC-3’ 
SA fix-rev 5’-Phosphate-GTGACCTGCAGAGAGGGGAAGAAGTTAGTAACTCTTGTCATGTC-3’ 
fused-fwd 5’GAGACCCCTGCCCAGGGACCACCGACCCACCACCGGGAGCTCACTTACAGGCTCTCTACTT 
     AGTCCAGCACGAAGTCTG-3’ 
fused-rev 5’CAGACTTCGTGCTGGACTAAGTAGAGAGCCTGTAAGTGAGCTCCCGGTGGTGGGTCGGTG      
     G TCCCTGGGCAGGGGTCTC-3’ 
pCMV-Env-fwd 5’-phosphate-GACATGGCGCGTTCAACGCTCTC-3’ 
pCMV-Env-rev 5’-Phosphate-AAGCTTGGGTCTCCCTATAGTGAGTC-3’ 
SA fix fwd 5’-GACATGACAAGAGTTACTAACTTCTTCCCCTCTCTGCAGGTCAC-3’ 
SA fix rev 5’-GTGACCTGCAGAGAGGGGAAGAAGTTAGTAACTCTTGTCATGTC-3’ 
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The ORF 1, ORF 1+2, ORF 3, pEnv pft Splice donor, pEnv Fused and pCMV- 
Env variants were constructed using pcDNA-MoMLV Env as the template.  The 
ORF 1+2+3 variant was constructed using the ORF 1+2 variant as the template using the 
ORF 3 primer pair. pEnv Fused was constructed by using pcDNA-MoMLV Env as the 
template with the Fused primer pair. The pEnv pft Splice acceptor variant was initially 
made using pcDNA-MoMLV Env with the p-Splice acceptor primer pair, which resulted 
in a variant containing the sequence 5’-agcccctctctgcaggctcacttaca-3’.  This variant was 
subsequently used as a template with the SA fix primer pair to obtain the pEnv pft Splice 
acceptor.  The pEnv pft SD + SA variant was constructed using the pEnv pft Splice 
acceptor as a template in conjunction with the p-Splice Donor primer pair.  For 
construction of the pEnv Actin Intron variant, the pCAGGS vector was digested with Eco 
R1, Hinf 1, and Pst 1. The 1056 bp DNA fragment containing the intron from a chicken β 
actin gene (Accession number X00182) including its splice donor and splice acceptor 
sequences was isolated, its ends blunted using the Klenow fragment of the E.coli DNA 
Polymerase and then ligated into thePml 1 site of the pEnv Fused variant.    
 
 The PCR parameters to create p-Splice acceptor were as follows; anneal at 60 oC, 
extend at 68 oC for 5 cycles, then to push reaction towards desired product, the anneal 
temperature was raised to 65 oC and extend at 68 oC for 20 cycles. This did not result in 
desired product, instead sequence read 5’-agcccctctctgcaggctcacttaca-3’ This plasmid 
was termed transitional Splice acceptor and used as a template to create pEnv Splice 
acceptor using the same PCR parameters as above with the SA fix fwd and SA fix rev 
primers.  pCMV-AUG was constructed using pcDNA-MoMLV Env as the template.  The 
PCR parameters were as follows; anneal at 50 oC, extend at 68 oC for 5 cycles then switch 
annealing temperature to 55 oC and extend at 68 oC for 20 min. 
 
 
Virus production, titration, and western blot analysis 
 
  H1-BAG cells were seeded at approximately 25% confluence in 100-mm dishes 
and two days later fresh medium was added.  When cells reached 85% confluency, 2, 5, 
or 15 μg of a pcDNA-MoMLV Env construct and 25 μg of pcDNA MoMLV gag/pol 
construct were transfected into them using calcium phosphate co-precipitation.  After 24 
hr the medium was replaced with 10 ml fresh DMEM containing 8% FBS.  Twenty-four 
hr later the virus supernatant was collected and filtered through a 0.45 µm filter.  A 2 ml 
aliquot was used to quantify infection by end point dilution on NIH 3T3 cells seeded at 
10% confluency in 24-well plates.  Cells were exposed overnight to 10-fold serial 
dilutions of virus containing 20 μg of polybrene/ml.  Forty-eight hr later cells were fixed 
and stained with 5-bromo-4-chloro-3-indolyl β-D-galactopyranoside.  The virus titer was 
calculated as the Tissue Culture Infectious Dose 50 (TCID 50) from the end point 
dilution.  The remaining 8 ml of virus supernatant was pelleted by ultracentrifugation 
using a Beckman SW40 rotor at 30,000 rpm for 90 min at 4oC.  Virus pellets were 
resuspended in 40 μl of ice cold PBS.  Ten μl of virus pellet was mixed 1:1 with 2x 
loading buffer [104], boiled for ten min, chilled on ice, then electrophoresed through an 
8% SDS-PAGE and transferred to a nitrocelluose membrane (Protran,Schleicher and 
Schuell).  The membrane was cut in half at the 50 kDa molecular mass marker, blocked 
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for 2 hrs in 6 % dry milk, and 2 % Tween 20. The top half was probed for the surface 
protein (SU) using goat anti-gp70 antiserum (Quality Biotech no. 80S000018; 1:100), 
and the bottom was probed for capsid protein (CA) with goat anti-p30 antiserum (Quality 
Biotech no. 80S000018; 1:100) for one hr.  The primary antibody was detected by 
incubation with mouse anti-goat antibody conjugated to horseradish peroxidase (1:5,000) 
for 45 min followed by incubation with SuperSignal West Pico Chemiluminescent 
Substrate (Pierce). 
 
 
Results 
 
 
Increasing pcDNA-MoMLV Env positively affects Env expression and recombinant 
MoMLV infectivity 
 
 Recombinant MoMLV was produced by transfecting the pcDNA-MoMLV Env 
and pcDNA MoLV Gag/Pol into H1-BAG cells [125].  The level of MoMLV envelope 
transfected was either 2, 5, or 15 µg.  As the amount of plasmid increased so did the 
amount of envelope protein present in the virus production as detected by western blot 
analysis (Figure 4-1A).  The MoMLV CA, which represents the physical particles 
produced, was used as a loading control and is observed to be at a similar level 
throughout all three samples.  This shows that the increase in Env is not due to the 
presence of more virus particles.  
 
 Each of these virus productions was tested for the ability to infect NIH 3T3 cells.  
Infection was determined by expression of the marker LacZ gene in an end point dilution 
assay.  The level of infection corresponded with the amount of envelope protein 
expressed (Figure 4-1B).  Almost a twenty-fold increase in infectivity was observed 
when fifteen vs. two µg of envelope plasmid was used.  Increasing the amount pcDNA-
MoMLV Env leads to increased Env expression and increased recombinant MoMLV 
infectivity.  
 
 
Mutations of the short open reading frames in the 5’ untranslated region of the 
MoMLV envelope gene 
  
 In pcDNA-MoMLV Env, there are three ORFs that are directly upstream of the 
natural ribosomal initiation site (Figure 4-2).  The role of these upstream ORFs was 
investigated by performing site-directed mutagenesis  The nucleotide sequences, but not 
the amino acid sequences of pcDNA-MoMLV Env were altered to eliminate the ORFs .  
Each one is designated either ORF 1, ORF 2, or ORF 3 based on its orientation from the 
5’ terminus of the plasmid.  Four constructs were made: the first eliminated ORF 1, the 
second eliminated ORF1 and ORF 2, the third eliminated ORF 3, and the fourth 
eliminated all three ORFs. 
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Figure 4-1.  Western blot and titer analysis of virus produced with pcDNA-MoMLV 
Env.  Recombinant MoMLV virus was produced by transfecting two, five, or fifteen µg 
of pcDNA-MoMLV Env and twenty-five µg of a pcDNA MoMLV Gag/Pol plasmid into 
H1-BAG cells.  A)  Western blot analysis of envelope production. Virus particles were 
purified by ultracentrifugation and separated via 8% SDS-PAGE.  Proteins were 
transferred to nitrocellulose and the membranes were cut in half at the 50 kDa marker 
band.  The top half of the membrane was incubated with anti-SU antiserum to detect the 
70 kDa surface unit (SU) protein of the viral envelope.  The bottom half of the membrane 
was incubated with anti-capsid antiserum to detect the viral capsid (CA) which acts as a 
loading control.  B) Infection level on NIH 3T3 cells using increasing amounts of 
pcDNA-MoMLV Env.  NIH 3T3 cells were exposed to viral supernatant and infection 
was quantified by end point dilution of cells expression the Lac Z gene.  Values are 
shown as a log scale representation of the mean ± standard deciation of three independent 
experiments.   
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Figure 4-2.  Schematic diagram of upstream ORFs found in pcDNA-MoMLV Env.  
The black arrow indicates the translation initiation site of the envelope protein.  The three 
upstream ORFs are depicted in the context of their sequence.  ORF 1 and ORF 2 are not 
in the same reading frame and are not in an optimal Kozak sequence.  ORF 3 is in the 
correct reading frame surrounded by an optimal Kozak sequence.  There are 379 
nucleotides between ORF 1 and the true translation initiation site.  Also depicted are the 
unique 3’ (U3), repeat (R), unique 5’ (U5), primer binding site (PBS), splice donor (SD), 
and splice acceptor (SA) sequences. 
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Recombinant MoMLV was produced by transfection using the same amount (2 
µg) of either pcDNA-MoMLV Env or the mutant constructs.  Western blot analysis of the  
virus productions illustrated that mutation of the three upstream ORFs did not lead to a 
change in the amount of Env (Figure 4-3A).  The level of Env expressed from pcDNA-
MoMLV Env is nearly identical to that of each mutant ORF construct.  This observation 
disproved the first hypothesis that the upstream ORFs were limiting or stalling ribosomes 
from actively translating Env mRNA from the natural AUG site.  To ensure Env 
produced from the ORF mutants was not affected in some other manner, each mutant was 
tested for its ability to infect NIH 3T3 cells (Figure 4-3B).  When compared to pcDNA-
MoMLV Env the level of infection by the mutants was not statistically significant based 
on a P value of 0.3.  The ORF 1 +2 +3 construct did show a slight reduction in titer.  
Based on the titer of the ORF 1 + 2 and ORF 3 mutants I believe this lower titer observed 
by ORF 1 +2 +3 is due to the quality of the DNA preperation used for transfection. 
 
 
Mutational analysis of the splice donor and splice acceptor region of the MoMLV 
envelope gene 
 
 To address the hypothesis that poor splicing was responsible for low envelope 
expression an array of constructs were generated by oligonucleotide directed mutagenesis 
using pcDNA-MoMLV Env as the template (Figure 4-4).  pEnv perfect (pft) Splice 
acceptor, pEnv pft Splice donor, and pEnv pft SD + SA all contained mutations making 
the SD or SA sequence match the consensus sequence for optimal splicing. The pCMV-
AUG construct was created by deleting the entire sequence between the CMV promoter 
and the true AUG start codon.  This eliminated the SD, SA, and the 5’ untranslated 
region and should not allow any splicing to take place.  pEnv Fused was designed so that 
the intronic sequence between the SD and SA was eliminated as if splicing had already 
take place. Using this construct as a template, the pEnv Actin Intron construct was 
designed to rescue the protein expression of Env by introducing a foreign SD and SA 
with a good consensus sequence.   
 
 In agreement with the hypothesis, western blot analysis demonstrated that 
mutations which should have improved splicing yielded higher levels of Env expression.  
Likewise mutations that should have inhibited splicing resulted in either reduced or 
undetectable Env expression (Figure 4-5A).  There was a direct correlation between the 
number of nucleotides needed to make the splice site match the consensus sequence and 
the level of Env expression.  The SD only needed a few mutations to match the perfect 
consensus sequence and therefore only improved the protein expression by a small 
margin.  The SA required many more mutations to match the perfect consensus sequence 
and showed a greater level of protein expression when these mutations were made.  The 
construct pEnv pft SD + SA, which had both a perfect SD and SA sequence, produced the 
highest amount of protein expression.  The pEnv Fused and pCMV-AUG construct, 
which should not permit splicing to take place, did not produce any detectable amounts of 
Env.  The rescue of the pEnv Fused construct by the addition of the actin intron further 
supports the hypothesis that improved splicing is the cause of increased Env expression. 
Each recombinant MoMLV production was tested for the ability to infect NIH 3T3 cells  
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Figure 4-3.  Western blot and titer analysis of virus produced using ORF envelope        
constructs.  Recombinant MoMLV virus was produced by by transfecting two µg of 
envelope construct along with twenty-five µg of a MoMLV Gag/Pol plasmid into H1-
BAG cells.  A)  Western blot analysis of envelope production for the different 
envelope constructs. Virus particles were purified by ultracentrifugation and separated 
via 8% SDS-PAGE.  Proteins were transferred to nitrocellulose and the membranes were 
cut in half at the 50 kDa marker band.  The top half of the membrane was incubated with 
anti-SU antiserum to detect the 70 kDa surface unit (SU) protein of the viral envelope.  
The bottom half of the membrane was incubated with anti-capsid antiserum to detect the 
viral capsid (CA) which acts as a loading control.  B)  Infection level on NIH 3T3 cells 
of virus produced with each of the different envelope constructs.  NIH 3T3 cells were 
exposed to viral supernatant and infection was quantified by end point dilution of cells 
expression the Lac Z gene.  Values are shown as a log scale representation of the mean ± 
standard deviation of three independent experiments.  (TCIU)  Statistical difference was 
calculated by performing a student t-test.  P values were 0.68, 0.43, 0.84, and 0.32 for 
ORF 1, ORF 1+2, ORF 3, and ORF 1+2+3 respectively. 
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Figure 4-4.  pcDNA-MoMLV Env and derived splicing mutants.  Mutations made to 
the key regions, including the splice donor (SD), splice acceptor (SA) and branch point 
(BP) are shown.  Mutations generated in these regions are underlined and deletions are 
marked by (-).  The pEnv Fused plasmid was deleted for the entire sequence between the 
SD and SA.  pEnv Actin Intron was generated by inserting an intron from the chicken β 
actin gene (Accession number X00182) into the pEnv Fused plasmid.  pCMV-AUG was 
deleted for the 5’ untranslated region, which brought the AUG ribosomal start site 
immediately downstream of the pCMV promoter. Arrow indicates initiation of 
transcription.  Also depicted are the unique 3’ (U3), repeat (R), unique 5’ (U5), and 
primer binding site (PBS). 
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Figure 4-5.  Western blot and titer analysis of virus produced using splicing                           
envelope constructs.  Recombinant MoMLV virus was produced by by transfecting two 
µg of pcDNA MoMVL Env or mutant construct along with twenty-five µg of a MoMLV 
Gag/Pol plasmid into H1-BAG cells.  A)  Western blot analysis of envelope production 
for the different envelope constructs. Virus particles were purified by 
ultracentrifugation and separated via 8% SDS-PAGE.  Proteins were transferred to 
nitrocellulose and the membranes were cut in half at the 50 kDa marker band.  The top 
half of the membrane was incubated with anti-SU antiserum to detect the 70 kDa surface 
unit (SU) protein of the viral envelope.  The bottom half of the membrane was incubated 
with anti-capsid antiserum to detect the viral capsid (CA) which acts as a loading control.  
B)  Infection level on NIH 3T3 cells by virus produced using each of the different 
envelope constructs.  NIH 3T3 cells were exposed to viral supernatant and infection was 
quantified by end point dilution of cells expression the Lac Z gene.  Values are shown as 
a log scale representation of the mean ± standard deviation of three independent 
experiments.  
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(Figure 4-5B).  The level of infection, based on an end point dilution assay of each virus, 
directly correlated with the level of Env expression.  Virus produced from  constructs that 
contained improved SD or SA sequences lead to and increase in titer when compared to 
pcDNA-MoMLV Env.  Virus produced with pEnv Fused or pCMV-Aug constructs 
displayed approximately a ten fold decrease in titer despite the having a similar level of 
physical particles.  The pEnv Actin Intron construct was able to restore the viral titer to 
levels close to that of the pSD + SA construct.   
 
 
Discussion 
 
 
Cis-elements are important in retroviral vectors 
 
 Retroviral vectors like MLV have been extremely important tools in molecular 
biology as well as gene therapy [135, 136].  The retroviral genome is small but is 
extremely efficient.  It contains many known cis acting sequences that allow a single 
genomic transcript to code for multiple proteins as well as interact with many cellular and 
viral proteins that provide assistance through different stages of the retroviral lifecycle.   
Through natural selection, the full length genome of the virus has become optimized for 
interaction with its host cell through the use of these cis-elements.  One goal in creating 
retroviral vectors is to eliminate as much of the viral sequence as possible to prevent the 
occurrence of replication competent retroviruses caused by homologous recombination 
[137].  In doing so, many of the cis-elements are excluded or misused.  When used in the 
proper context these elements can be exploited to boost titer and gene expression from 
retroviral vectors.  Some examples include the central polypurine tract (cPPT) that 
enhances nuclear translocation of the preintegration complexes in HIV-1, SIV, and EIAV 
[138] or the woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) 
that helps to stabilize the mRNA therefore increasing protein expression [139-141].  The 
results from this study demonstrate the pitfalls using cis-elements out of the context of 
the entire genome.  The SA sequence found within the MoMLV genome works in concert 
with many other cis-elements to regulate splicing so that optimal MoMLV replication is 
obtained.  However, this same SA sequence used in the context of pcDNA-MoMLV Env 
plasmid inhibited maximal expression. 
 
  In this case, the upstream ORFs did not interfere with the expression of the 
MoMLV envelope protein or infection of virus produced with these ORF mutants.  
Hildinger et. al. [127] reported that deletion of aberrant ORFs improved gene expression 
slightly in the 5’ LTR of retroviral vectors, pointing out concern for toxicity and 
immunogenicity of proteins possible expressed from these ORFs.  The conflicting results 
can probably be explained by the small increase in protein expression observed and the 
greater sensitivity of the assay used by Hildinger and colleagues [127].  In the context of 
gene therapy the deletion of deviant upstream ORFs may prove to be at worst a neutral 
modification.   
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Splicing in MLV is regulated by multiple cis-elements including the splice acceptor 
 
 Regulation of alternative splicing in retroviruses occurs due to interactions 
between viral cis-acting sequences and cellular splicing factors including the spliceosome 
[142, 143].  In eukaryotic cells splicing is catalyzed by the spliceosome.  The 
spliceosome complex is an RNA-Protein aggregate which has been estimated to contain 
several hundred different proteins in addition to five spliceosomal snRNAs [144-147].  
Alternative splicing of HIV-1, a complex retrovirus and ASV, a simple retrovirus are 
very well studied.  Both of the viruses use a sub-optimal 3’ SA to regulate splicing [133, 
148, 149].  By having a sub-optimal SA the host cell splicing machinery cannot 
efficiently splice the viral transcript, which provides the correct ratio of spliced and 
unspliced message for optimal viral replication.  MLVs also contain a sub-optimal 3’ 
splice acceptor [150] and until recently were thought to regulate splicing by this same 
mechanism.  However it was shown the MLV splice acceptor can be replaced with one 
containing the optimal consensus sequence and unspliced transcripts are still produced 
[151].  This suggested an alternate mechanism for regulation.  It was then shown that 
contrary to HIV-1 and ASV, MLV regulates splicing through the 5’ splice donor [152].  
The splice donor of MLV matches the consensus sequence almost perfectly but is 
regulated by upstream cis-elements which form an inhibitory stem-loop around the SD 
[152].   
 
 The evidence in this study suggests that it is very likely that the MLV SA does in 
fact play a role in the regulation of spliced message.  Mutating the SD and SA of pcDNA-
MoMLV Env to match the consensus sequence resulted in an increase of envelope 
expression.  The mechanism is most likely do to an increase in splicing efficiency leading 
to better nuclear export of the transcript.  This hypothesis was further supported by the 
pEnv Actin Intron construct, which showed the observed effect is directly due to the 
splicing sequence.  However, the apparent role of the sub-optimal SA in pcDNA-
MoMLV Env may not be the same when placed in the context of the virus genome.  
Many other cis-elements exist in retroviruses that regulate splicing both positively and 
negatively: exonic splicing enhancer (ESE), intronic splicing silencer (ISS), negative 
regulator of splicing (NRS), exonic splicing suppressor (ESS) [10, 153].  In fact many 
retroviruses including ASV use a variety of cis-elements to regulate splicing [153], 
resulting in a highly complex and poorly understood process.  Due to the large number of 
signals involved it comes as no surprise that the ratio of transcripts produced by 
alternative splicing can vary depending on the environment [3, 10]. 
  
In conclusion, the results of this study suggest that the sub-optimal SD and SA in 
pcDNA-MoMLV Env regulate splicing.  It also suggests that the SA in MoMLV, like all 
other retroviruses, plays a role in the regulation of splicing.  To confirm the role the SA 
in MoMLV more experiments need to be carried out.  The SA of MoMLV should be 
mutated using site directed mutagenesis to match the consensus sequence.  These mutant 
clones should be transfected into NIH 3T3 cells along with wild type MoMLV clones as 
a control.  The cytoplasmic mRNA from these cells should be harvested and subjected to 
real time RT PCR.  The primers used should be able to detect either full length MoMLV 
mRNA or spliced MoMLV mRNA.  This will allow for quantification of the two forms.  
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The ratio of these forms can be compared to that of the ratio of the control sample.  This 
should establish if there is a difference in the level of splicing taking place.  If the SA in 
MoMLV regulates splicing then changing the sequence to a perfect SA would change the 
natural ratio of full length vs. spliced mRNA.  An increase in the amount of spliced Env 
mRNA and a decrease in full length genomic mRNA would occur.   This would result in 
a decrease in progeny virus production by lowering the amount of full length transcript 
available for translation and viral genome.  However, the progeny virus would likely be 
more infectious do to an increase in the amount of envelope protein incorporated.  This 
could be investigated by transfecting NIH 3T3 cells with either a wild type molecular 
clone or a clone containing the perfect SA and examining their growth kinetics.  Wild 
type virus would be expected to produce higher levels of progeny virus and therefore 
spread faster than virus produced from the SA clone.  Over time, the virus produced from 
the SA clone should accumulate mutations including ones that revert the perfect SA back 
to an imperfect sequence that restores the balance of mRNA.  The progeny acquiring 
these mutations should emerge as the dominant variant.   
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Chapter 5.  Discussion 
 
 
There are many steps in the life cycle of a retrovirus.  Some are well defined 
while others remain essentially a mystery.  This study brings to light new information 
about retrovirus entry, primer tRNA deaminoacylation, and splicing.  To begin an 
infection the virus must gain entry to the host cell cytoplasm.  After receptor binding 
retroviruses undergo a membrane fusion step that occurs via rearrangements of the viral 
glycoprotein which allow the fusion peptide to become exposed.  Low pH, receptor 
engagement, and protease cleavage are mechanisms used by enveloped viruses to trigger 
these rearrangements.  Currently, MoMLV membrane fusion is thought to be pH 
triggered.  However, the pH dependence observed for MoMLV may actually reflect a 
requirement for the activity of host cell cathepsins, instead of a pH trigger for membrane 
fusion.  MoMLV enters through the endocytic pathway where it would likely encounter 
members of the cathepsins family.  Many of the different cathepsins examined were able 
to cleave MoMLV SU and therefore may be implemented during the membrane fusion 
step.  Similar observations have been made outside the field of retrovirology in both the  
Paramyxoviridae and Filoviridae families; cathepsins are either known or implemented to 
trigger the membrane fusion step. 
 
Retroviruses begin reverse transcription of their genome shortly after budding and 
complete it after gaining entry to the host cell cytoplasm.  The RT of all retroviruses use 
host cell tRNAs to prime reverse transcription.  In order for RT to initiate synthesis, the 
tRNA must first be deaminoacylated.  The only known mechanism for primer 
deaminoacylation in retroviruses is that of AMV.  AMV appears to accomplish this via 
the hydrolase activity found within its RT.  HIV-1 RT on the other hand does not appear 
to have similar levels of hydrolase activity towards its cognate primer.  This suggests that 
HIV-1 and perhaps other retroviruses use a different strategy to achieve this task.  Unlike 
AMV, HIV-1 is a complex retrovirus and encodes several other accessory proteins.  The 
proteins as well as cellular proteins recruited by HIV-1 could play a role in 
deaminoacylation.   
 
Once the RNA genome is completely reverse transcribed into double stranded 
DNA it becomes integrated into the host cell chromosomal DNA.  The provirus is 
transcribed, modified, and spliced by the host cell machinery.  The ratio between full 
length and spliced mRNA is critical for optimal viral infectivity and must be tightly 
regulated.  This regulation occurs through a variety of different mechanisms.  This study 
implicates the use of a sub-optimal 3’ SA by MoMLV.  This mechanism was first 
discovered in the avian retroviruses and seems to be common to most simple retroviruses.  
By evolving sub-optimal SA retroviruses reduced the efficiency with which their mRNAs 
are spliced as a form regulation.  Other forms of regulation include a variety of splicing 
enhancer and suppressor sequences, which can be further regulated by secondary 
structure within the mRNA transcript itself.   
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Appendix 
 
 
Introduction 
 
 
Aminoacyl-tRNA synthetases  
  
 There are 20 different Aminoacyl-tRNA synthetases (aaRS).  Each aaRS is 
capable of charging all of its cognate tRNAs and can discriminate from all other tRNAs 
with great efficiency [116].  In an ATP dependent reaction called aminoacylation, the 
synthetase links an amino acid to the free 2’ or 3’ hydroxyl group of the adenosine 
located at the 3’ terminus of the tRNA via an ester bond [1, 154, 155].  aaRSs fall into 
two main classes based on structural motifs.   These structural motifs define how they 
interact with and charge their cognate tRNA; class I charges the 2’-OH while class II 
charges the 3’-OH.  Located in the cytoplasm of  higher eukaryotic cells is a multi-
enzyme complex containing glutamyl-, prolyl-, isoleucyl-, leucyl-, methionyl-, 
glutaminyl-, lysyl-, arginyl-, and aspartyl-tRNA synthetases called the MARS complex 
(Multi-Aminoacyl-tRNA Synthetase) [156].  Interestingly, there are exactly ten class I 
and ten class II aaRS and the MARS complex is a hodge-podge of both classes. 
 
 
Two forms of LysRS 
 
In eukaryotic cells the majority of the twenty aaRSs are found in two forms; either 
a mitochondrial or cytoplasmic form.  Despite mitochondria having their own genome the 
mitochondrial aaRSs are nuclear encoded proteins, synthesized in the cytosol then 
imported into the mitochondria [157].  The two forms of the protein result from separate 
genes or from an alternative splice of the same gene [158].  LysRS, a class II enzyme in 
eukaryotic cells is found both in the mitochondria and in the cytoplasm where it is 
associated with the MARS complex.  The two forms which share 576 identical amino 
acid residues arise from an alternative splicing event and differ only at their amino 
terminus [124, 159].  As discussed in chapter three HIV-1 specifically recruits its primer, 
tRNALys3 into the virion by recruiting the cognate synthetase LysRS  [83, 90].  Growing 
evidence indicates that it is the mitochondrial form of the aaRS that is recruited into the 
HIV-1 virion.  The first clue was that other members of the MARS complex could not be 
detected in HIV-1 virions [88].  The previous work done to identify LysRS in HIV-1 was 
performed using polyclonal antibodies that could not differentiate between the two forms 
[82].  Recently Marc Mirande and co-workers generated antibodies to synthetic peptides 
matching residues 1-19 of human cytoplasmic LysRS and residues 25-42 of human 
mitochondrial LysRS [124].  Using these antibodies they showed that the LysRS in HIV-
1 reacted with the mitochondrial specific antibody and not the cytoplasmic [124]. 
MMTV, like HIV-1,  uses tRNALys3 as its primer for replication and specifically recruits 
tRNALys  isoacceptors into the virion during the assembly process [70].  However, the 
mechanism for this specific recruitment is currently unknown. The goal of these 
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experiments was to determine if LysRS is packaged by MMTV and if so, determine 
which form is of LysRS is present. 
 
 
Materials and methods 
 
 
Previously described protocols 
 
 The methods used to propagate cells and prepare cell lysates and crude 
purification of murine synthetase are described in chapters two and three. 
 
 
MMTV production and western blot analysis 
   
 The pHP plasmid encoding an infectious molecular clone of MMTV was 
introduced into NIH 3T3 cells by calcium phosphate transfection [160].  Cells were then 
grown in DMEM containing 8 % fetal bovine serum (FBS) and  G418 (250 µg/ml) to 
select for cells containing the plasmid.  Virus containing supernatant was collected 48 hrs 
after cells reached 100 % confluence and filtered through a 0.45 µm filter.  The filtrate 
was subjected to ultracentrifugation using a Beckman SW40 rotor at 30,000 rpm for 90 
min at 4oC.  Virus pellets were resuspended in 40 μl of ice cold PBS.  Ten μl of virus 
pellet was mixed 1:1 with 2x loading buffer [104], boiled for ten min, chilled on ice, then 
electrophoresed through an 10-20% SDS polyacrylamide gel and transferred to a 
nitrocelluose membrane (Protran, Schleicher and Schuell).  The membrane was cut in 
half at the 37 kDa molecular mass marker, blocked for 2 hrs in 6 % dry milk, 2 % Tween 
20, then the top half was probed for LysRS using rabbit anti-KRS (1:1000 ) [161], and 
the bottom half was probed for the MMTV capsid protein (p27) by incubation with 
undiluted mouse monoclonal anti p-27 antibodies [162] for two hrs.  The primary 
antibodies were detected by incubation with goat anti-mouse antibody conjugated to 
horseradish peroxidase (1:10,000) for 45 min followed by incubation with SuperSignal 
West Pico Chemiluminescent Substrate (Pierce). 
 
 After exposure membranes were stripped by incubation with Restore Western 
Blot Stripping Buffer (Pierce) according to the manufacturer’s protocol, with two 
exceptions. First, the incubation temperature was increased to 37 ˚C.  Second, the time of 
incubation was increased to 25 min and including an additional 10 min at room 
temperature with constant rocking.  The membrane was cut in to pieces at the 37 kDa 
mark.  Each half was incubated with either rabbit anti-cytoplasmic KRS (anti-cKRS) or 
anti-mitochondrial KRS (anti-mKRS) antibodies (1:10,000) (gift from Marc Mirande) 
overnight in blocking solution.  The primary antibodies were detected by incubation with 
goat anti-rabbit antibody conjugated to horseradish peroxidase (1:5,000) for 45 min 
followed by incubation with SuperSignal West Pico Chemiluminescent Substrate 
(Pierce). 
 
 
77 
 
Results 
 
 MMTV was produced by transfection of the pHP plasmid into NIH 3T3 cells 
[160].  Virus was pelleted by ultracentrifugation of the cell culture supernatant, the viral 
proteins were separated by SDS-PAGE, transferred to a nitrocellulose membrane, and 
subjected to western blot analysis.  The top half of the membrane was probed with a 
polyclonal antibody against LysRS and the bottom half was probed with a monoclonal 
antibody for p27 the capsid protein of MMTV (Figure A-1).  Three main observations 
were made in this analysis.  First, the MMTV samples contained LysRS but it was 
slightly smaller in size when compared to the positive controls (NIH 3T3 cell lysate and 
crude murine synthetase preparation).  Second, unexpectedly the supernatant of NIH 3T3 
cells that were not transfected with pHP plasmid contained LysRS and contained some 
form of anti-p27 reactive protein as well.  Unfortunately, without a true negative control 
it cannot be concluded that the LysRS present was incorporated in MMTV.  Lastly, upon 
a longer exposure of the western blot, p27 was present in all of the samples.   
 
 Next, the top section of the membrane was stripped and cut in half.  Each half 
contained identical samples.  The left side was probed with anti-mLysRS (mitochondrial 
LysRS) and the right side was probed with anti-cKRS (cytoplasmic LysRS) (Figure A-2).   
Anti-mLysRS did not show specificity and reacted with several other proteins, thus it 
cannot be determined if mLysRS is actually present in any of the samples.  cLysRS was 
detected in the MMTV sample however it was also detected in what should have been the 
negative control.  Since this antibody was generated to a synthetic peptide matching the 
human form of LysRS it may be not as sensitive against mouse cLysRS.  cLysRS can 
easily be detected in human 293 cell lysates but not in mouse NIH 3T3 cell lysates (data 
not shown).  Therefore, it is interesting that the amount of cLysRS present in the 
supernatant and synthetase preparation is detectable.      
 
 
 
Discussion 
 
 The unexpected presence of MMTV capsid in all of the samples was 
disappointing and precluded determining if LysRS is truly present within MMTV virions 
or merely in the NIH 3T3 supernatant.  However this work does invoke some interesting 
discussion.   
 
 Why do the negative control NIH 3T3 cells contain p27?  One explanation is 
contamination with MMTV.  The pHP plasmid produces fully infectious MMTV capable 
of infecting and replicating in other cells.  Both cell lines were handled in the same area 
of the lab and therefore contamination would be possible.  However, p27 is also detected 
in the crude murine synthetase preparation.  As described in the materials and methods of 
chapter 3 this preparation is made by column purification of the liver homogenate from 
B6 mice.  This suggests that the presence of p27 in both samples is the result of active 
endogenous MMTV.  To eliminate this problem the experiment could be carried out in  
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Figure A-1.  Detection of lysine synthetase in MMTV.  Samples were separated on a 
10-20 % SDS-PAGE gradient gel.  The proteins were transferred to nitrocellulose and the 
membrane was cut in half just below the 37 kDa molecular mass maker.  The top portion 
of the membrane was incubated with polyclonal anti-KRS antibody to detect lysine 
synthetase, while the bottom half was incubated with monoclonal anti-p27 antibody to 
detect MMTV capsid protein. 
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Figure A-2.  Detection of the cytoplasmic and mitochondrial forms of lysyl 
synthetase in MMTV.  The top half of the membrane from Figure A-1 was cut in half 
vertically then stripped and re-probed.  Lanes 1-4 were incubated with anti- cKRS and 
lanes 5-8 were incubated with anti-mKRS.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
80 
 
 
human 293 cells transfected with mouse transferrin receptor 1, the MMTV receptor 
[163].  It should be noted though that it is possible that MMTV could recruit mouse 
LysRS but not human.   
 
What could the small size difference observed between LysRS detected in the 
supernatant samples versus that detected in the NIH 3T3 lysate and synthetase 
preparation (Figure A-1) be?  Assuming MMTV recruits the LysRS one explanation that 
could account for this is cleavage by the viral protease.  LysRS may contain a sequence 
or motif that is recognized by the viral protease.  Figure A-2 shows that the cytoplasmic 
form of LysRS is present and this form is normally associated with the MARS complex.   
Cleavage of LysRS could free it from the MARS complex and allow its specific 
recruitment into the virion.  This hypothesis could also explain the difference in the 
relative abundance of LysRS seen in each sample.  Using the polyclonal LysRS antibody, 
a much greater amount of LysRS protein was detected in the cell lysate than in the 
supernatant samples (Figure A-1).  However, when the same samples were probed with 
cKRS the inverse was true (Figure A-2).  The truncated version of LysRS could be 
missing key epitopes for the polyclonal antibody resulting in underestimation of the 
amount of protein observed in the supernatant samples. 
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